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Proclaim! And thy Lord is Most Bountiful,- He Who taught (the use 
of) the pen,- Taught man that which he knew not.
Man We did create from a quintessence (of clay); Then We placed 
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creature. So blessed be Allah, the best to create! After that, at length 
ye will die. Again, on the Day of Judgment, will ye be raised up.
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LIST OF ABBREVIATIONS 
 
AC     Adenylyl cyclase 
app.     Approximately 
APS     Ammonium per sulfate 
ATP     Adenosine-5-triphosphate 
bFGF     Basic fibroblast growth factor 
BSA     Bovine serum albumin 
CaCl2     Calcium chloride 
CaMKII     Ca2+/calmodulin-dependent protein kinase II 
cAMP     3'-5'-cyclic adenosine monophosphate 
cGMP     3'-5'-cyclic guanosine monophosphate 
CPI-17    PKC-potentiated inhibitor 17-kDa protein 
DMSO    Dimethyl sulfoxide 
DTT     Dithiothreitol 
EC     Endothelial cells 
ECGS     Endothelial cell growth supplement 
ECL     Enhanced chemiluminescence 
EC-MLCK    Endothelial cell myosin light chain kinase 
EDTA     Ethylene diamine tetraacetic acid 
EGTA     Ethylene glycol-bis(2-aminoethylether)-N,N,N',N'- 
tetraacetic acid 
F-actin    Filamentous actin 
FCS     Fetal calf serum 
FSK     Forskolin 
GPCR    G-protein-coupled receptors 
G-actin    Globular actin 
HBSS     Hanks' balanced salt solution 
hEGF     Human epidermal growth factor 
HEPES    4-(2-hydroxyethyl)-1-piperazine ethane sulfonic 
acid  
HUVEC    Human umbilical vein endothelial cells 
IU     International unit 
KCl     Potassium chloride 
  
2
 
KH2PO4    Potassium dihydrogen phosphate 
ILK     Integrin linked kinase 
kDa     Kilo dalton 
MgCl2     Magnesium chloride 
min     Minutes 
MLC     Myosin light chain 
MLC~P    Monophosphorylated myosin light chain 
MLC~PP    Diphosphorylated myosin light chain 
MLCK     Myosin light chain kinase 
MLCP     Myosin light chain phosphatase 
MnCl2     Manganese chloride 
MYPT1    Myosin phosphatase targeting subunit 1 
NaCl     Sodium chloride 
NaF     Sodium fluoride 
Na2HPO4    Di-sodium hydrogen phosphate  
NaH2PO4    Sodium dihydrogen phosphate 
Na-orthovanadate   Sodium orthovanadate  
NP-40     Nonidet P-40 
PAK     p21-activated kinase 
PAR1     Protease-activated receptor-1 
PBS     Phosphate-buffered saline 
pH     Negative log of H+ concentration  
PKA     Protein kinase A 
PKC     Protein kinase C 
PKI     Protein kinase A inhibitor 
PMA     Phorbol-12-myristate-13-acetate 
PMSF     Phenylmethylsulfonyl fluoride 
PP1     Protein phosphatase 1 
rec. I-2    Recombinant inhibitor 2 
Rhotekin-RBD   Rho-binding domain of rhotekin 
Rock     RhoA-dependent kinase 
S19     Serine 19 
SDS     Sodium dodecyl sulfate 
SMC     Smooth muscle cells 
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SMC-MLCK    Smooth muscle cell myosin light chain kinase 
Soln.     Solution 
T18     Threonine 18 
T38     Threonine 38 
T696     Threonine 696 
T850     Threonine 850 
TBS     Tris-buffered saline  
TCA     Trichloroacetic acid 
Thr     Thrombin 
TEMED    N, N, N’, N’,-tetramethylethylenediamine 
Tris    Tris(hydroxymethyl)aminomethane  
VE-cadherin    Vascular endothelial cadherin 
% vol/vol    Volume by volume percentage 
% wt/vol    Weight by volume percentage 
ZIPK      Zipper-interacting protein kinase 
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1 INTRODUCTION 
 
1.1 Barrier function of the vascular endothelium 
 
The vascular endothelium acts as a semi-permeable barrier between the 
vascular lumen and the interstitial spaces and extends over a wide surface area. It 
controls the passage of ions, solutes, macromolecules and leukocytes across the 
vessel wall. It is well known that loss of this barrier function leads to extravasation 
of blood components and may finally result in edema formation (Mehta and Malik, 
2006; Bazzoni, 2006).  
The endothelial barrier function is maintained by an equilibrium of 
competing contractile and adhesive forces generated by the actomyosin 
cytoskeleton and adhesive molecules located at cell-cell and cell-matrix contacts. 
Endothelial cells are tightly connected with each other via interactions of adherens 
and tight junctional proteins of adjacent cells. These proteins are linked to the 
cortical actin cytoskeleton present directly under the cell membrane (Furuse et al., 
1994; Ben-Ze’ev and Geiger, 1998; Vleminckx and Kemler, 1999). Inflammatory 
mediators like thrombin cause activation of the contractile apparatus, derangement 
of the actomyosin cytoskeleton, and loss of cell adhesions. This results in barrier 
failure, increased macromolecule extravasation, and edema formation in the 
inflamed tissue (Lum and Malik, 1996; van Hinsbergh 1997; Wojciak-Stothard et 
al., 1998). 
The present study focuses on the role of the endothelial contractile 
machinery in regulating endothelial barrier function under pathophysiological 
inflammatory conditions, during which activation of endothelial cells leads to 
edema formation and organ failure. It is well documented that agents which 
counteract contraction in smooth muscle cells can also reduce endothelial 
permeability (van Hinsbergh and van Nieuw Amerongen, 2002). In accordance, 
maneuvers increasing the intracellular levels of cyclic adenosine monophosphate 
(cAMP) can counteract imminent barrier failure induced by inflammatory mediators 
like thrombin (Qiao et al., 2003). Presently, the molecular mechanisms of this 
barrier protection are not completely understood. Thrombin activates the 
contractile machinery of endothelial cells mainly via inhibition of the myosin light 
chain phosphatase (MLCP) and activation of myosin light chain kinase (MLCK) 
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leading to phosphorylation of the small regulatory myosin light chains (MLC) (Zhao 
and Davis, 1999; Gündüz et al., 2003), the key regulatory element of the 
contractile machinery. Activation of the cAMP-dependent protein kinase A (PKA) 
pathway leads to activation of MLCP in smooth muscle cells (Azam et al., 2007) as 
well as in endothelial cells (Bindewald et al., 2004) which leads to 
dephosphorylation of MLC. In endothelial cells, dephosphorylation of MLC goes 
along with inactivation of the contractile machinery and this causes stabilization of 
the endothelial barrier (Tinsley et al., 2004).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.1  Schematic presentation of the mechanism of endothelial barrier failure 
induced by inflammtory mediators. Mediators like thrombin cause failure of 
endothelial barrier function mediated by intracellular signal transduction 
mechanism. Effectors of these mechanisms are: the contractile machinery, cell-
cell and cell-matrix adhesion structures and the actin cytoskeleton. 
Disintegration  of  cell 
 adhesion structures 
Barrier failure
Fragmentation of 
cytoskeleton 
Activation of contractile  
machinery 
Inflammatory mediators 
Signal transduction Signal transduction 
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The main objective of the present study was to elucidate the mechanism of 
cAMP/PKA-mediated activation of MLCP as an important molecular target for 
endothelial barrier protection. The study was performed with a well-established in 
vitro cell culture model, using monolayers of human umbilical vein endothelial cells 
(HUVEC). Thrombin was used as an inflammatory mediator to simulate the in vivo 
state of hyperpermeability while forskolin (FSK), a direct activator of adenylyl 
cyclase, was used to activate the cAMP/PKA pathway. 
 
1.2 Endothelial actomyosin cytoskeleton 
 
Like other eukaryotic cells, endothelial cells possess a functional 
cytoskeleton consisting of actin and myosin filaments. The first direct evidence of 
endothelial cell contraction, in response to permeability-increasing agonists, was 
given by Majno and co-workers (1961a; 1961b). Using electron microscopy, they 
demonstrated endothelial cell contraction and gap formation in intact capillaries 
exposed to inflammatory mediators. A primary function of the contractile apparatus 
in endothelial cells is to regulate endothelial barrier integrity. Endothelial cell-cell 
adhesion and thus barrier integrity is mainly dependent on the actin cytoskeleton. 
Disruption of actin cytoskeleton by C2 toxin and cytochalasin D led to loss of 
endothelial cell-cell and cell-matrix contacts and detachment of cells from the 
substratum (Schnittler et al., 2001), whereas phallacidin, an actin stabilizer, 
prevented agonist-mediated barrier dysfunction (Phillips et al., 1989).  
In endothelial cells actin and myosin filaments represent ~16% of total 
cellular protein (Wong and Gotlieb, 1990). Actin comprises about 5% of the total 
protein and exists in two different forms: in a filamentous form, called F-actin, and 
in a monomeric form, called G-actin (Tobacman and Korn, 1983). Actin filaments 
are dynamic structures, and the shift between the monomeric and the polymeric 
form of this protein plays a central role in several cell functions, especially in cell 
contraction and migration. In endothelial cells, about half of the actin is present in 
F-actin form, and half in G-actin form. Stress fibers are composed of bundles of F-
actin and myosin filaments and are the primary elements of the contractile 
machinery of endothelial cells (Dudek and Garcia, 2001). Inhibition of actin 
polymerization by cytochalasin D or latrunculin leads to actin depolymerisation and 
abrogates the contractile response to inflammatory mediators (Goeckeler and 
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Wysolmerski, 1995; Moy et al., 1996, Mehta et al., 2002). Stimulation of 
endothelial cells with thrombin increases polymerization of actin filaments, as 
determined by the conversion of G-actin to F-actin (Thurston and Turner, 1994; 
Ehringer et al., 1999) reduces cortical actin content and leads to reorganization of 
actin to form stress fibers (Goeckeler and Wysolmerski, 1995; Ehringer 1999, van 
Nieuw Amerongen et al., 2000a; 2000b). This increase in stress fiber formation 
leads to a change in endothelial cell shape (Vouret-Craviari et al., 1998), which is 
an important factor in increased endothelial gap formation.These results provide a 
concept that actin polymerization plays a key role in induction of endothelial 
contraction.   
 
1.3 Endothelial contractile machinery 
 
Endothelial contractile machinery consists of actin and myosin filaments, the 
activation of which is mainly regulated by the phosphorylation state of the 
regulatory MLC. The phosphorylation state of MLC is precisely regulated by 
balanced activities of MLCK and MLCP. Thus, the major components of 
endothelial contractile machinery are actin-myosin filaments, MLC, MLCK and 
MLCP. 
 
1.3.1 Myosin light chains  
 
MLC is a 20 kDa small protein and an important determinant of the state of 
contractile activation in endothelial cells. It was shown that phosphorylation of 
serine 19 (S19) (monophosphorylation) and/or threonine 18 (T18) 
(diphosphorylation) of the regulatory MLC not only increases actomyosin ATPase 
activity, but also shifts the equilibrium from the folded to unfolded myosin forms 
(Kamisoyama et al., 1994), thus providing the assembly and function of the 
contractile apparatus of the cells. After thrombin treatment, MLC phosphorylation 
is accompanied by an increase in the F-actin and decrease in G-actin contents in 
endothelial cells (Goeckler and Wysolmerski, 1995). Phosphorylation of MLC has 
been shown to be involved in the regulation of  permeability of cultured endothelial 
cells as well as intact isolated postcapillary venules and pulmonary microvessels in 
response to histamine and thrombin (Yuan et al., 1997; Vogel et al., 2000). The 
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relationship between MLC phosphorylation and interendothelial gap formation is 
only partly understood. It is clear, however, that activation of the contractile 
machinery leads to an increase in paracellular permeability. The maximal increase 
in MLC phosphorylation in response to an agonist such as thrombin precedes 
tension development and the increase in endothelial barrier permeability 
(Goeckeler and Wysolmerski, 1995; Moy et al., 1996; Moy et al., 2002). 
 
1.3.2 Myosin light chain kinase  
 
MLCK is a Ca2+/calmodulin-dependent enzyme that phosphorylates MLC at 
S19 and/or T18 (Goeckeler and Wysolmerski, 1995). In contrast to smooth muscle 
cell MLCK (SMC-MLCK), which is 110-130 kDa, endothelial cell MLCK (EC-
MLCK) is a 210-kDa protein (Dudek and Garcia, 2001). Structurally, EC-MLCK 
contains all the domains present in the smooth muscle form, but in addition, has a 
unique 922 amino acid NH2-terminal domain containing consensus sites that may 
be phosphorylated by diverse protein kinases, including PKA (de Lanerolle et al., 
1984; Garcia et al., 1997), PKC (Bogatcheva et al., 2003), p21-activated kinase 
(PAK) (Goeckeler et al., 2000), Src (Birukov et al., 2001), and Ca2+/calmodulin-
dependent protein kinase II (CaMKII) (Verin et al., 1998). It is well established that 
activation of EC-MLCK leads to endothelial cell contraction and barrier dysfunction 
in response to inflammatory mediators like thrombin and histamine (Dudek and 
Garcia, 2001), while inhibition of EC-MLCK, using pharmacological inhibitors like 
KT5926 or ML-7, abrogates the increase in vascular permeability (Yuan et al., 
1997; Tinsley et al., 2000). Recently, it has been shown that expression of a 
constitutive active form of EC-MLCK resulted in an elevated basal permeability of 
venules as well as venular endothelial cells in culture (Tinsley et al., 2000). The 
selective knockout of EC-MLCK in a mouse model resulted in protection against 
barrier failure induced by lipopolysaccharides (Wainwright et al., 2003) and burn 
injury (Reynoso et al., 2007). These studies indicate that EC-MLCK plays a critical 
role in agonist-induced endothelial barrier failure via activation of the contractile 
machinery.  
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1.3.3 Myosin light chain phosphatase  
 
MLCP is a holoenzyme consisting of a catalytic subunit (PP1), a regulatory 
subunit (MYPT1), which targets PP1 to myosin and a smaller subunit of 20 kDa 
(M20) of unknown function. In endothelial cells the primary function of MLCP is to 
dephosphorylate MLC at S19 and T18.  
 
PP1 catalytic subunit. The PP1 catalytic subunit in mammalian cells is encoded 
by three genes, α, γ, and δ (also called β). Alternative splicing generates α1, α2, γ1, 
and γ2 variants (Sasaki et al., 1990; Durfee et al., 1993). The resulting five 
isoforms have high sequence homology and are expressed in many different cell 
types. They share over 95% identity in the core catalytic domain. With the 
exception of α2, which has an N-terminal insert, the other isoforms differ mostly in 
their C-terminal sequence, sharing less than 50% identity. Substrate specificity is 
modulated by association with a large number of regulatory and/or inhibitory 
subunits. In endothelial cells it is well established that PP1δ is the predominant 
isoform of PP1 existing in the MLCP holoenzyme (Verin et al., 2000; Härtel et al., 
2007). 
 
Myosin phosphatase targeting subunit. The specific activity of PP1 of MLCP to 
dephosphorylate the MLC is dependent upon its binding to the regulatory subunit 
MYPT1. MYPT1 is a 130 kDa protein and plays a key role in determining the 
physical and functional integrity of the trimeric myosin phosphatase (Khatri et al., 
2001). PP1δ binds to the N-terminus and M20 to the C-terminus of MYPT1. 
Myosin binds to both C- and N-terminal of MYPT1. The N-terminal of MYPT1 
shows ~15 fold increased activity and ~10-fold higher affinity for phosphorylated 
MLC than the isolated catalytic subunit (Hartshorne, 1998; Hartshorne et al., 2004; 
Ito et al., 2004). 
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Fig. 1.2 Regulation of endothelial cell contractility: Phosphorylation of myosin light 
chain (MLC~P) is a key step in the regulation of the activation of the contractile 
machinery. Calcium/calmodulin (Ca2+/CM)-dependent myosin light chain kinase 
(MLCK) phosphorylates, while myosin light chain phosphatase (MLCP) 
dephosphorylates MLC. Activation of the contractile machinery leads to endothelial 
cell contraction and barrier failure, while inactivation to relaxation and barrier 
stabilization. 
 
1.3.4 Regulation of myosin light chain phosphatase activity via MYPT1 
phosphorylation 
 
The activity of MLCP can be regulated either through its regulatory subunit 
MYPT1 or through direct inhibition of the catalytic subunit PP1 by low molecular 
weight endogenous inhibitors. Stimulation of endothelial and nonendothelial cells 
with thrombin leads to activation of RhoA-dependent kinase (Rock), which induces 
phosphorylation of MYPT1 and inhibition of MLCP activity (Goeckeler and 
Wysolmerski, 2005; Pandey et al., 2006).  
Most of our understanding about the regulation of the contractile machinery 
by MYPT1 is based on data obtained primarily from smooth muscle cells and little 
from endothelial cells. Several studies have well documented that MLCP activity is 
regulated by phosphorylation of its targeting subunit (MacDonald et al., 2001; 
Wooldridge et al., 2004). The two main inhibitory phosphorylation sites identified in 
smooth muscle cells as well as in endothelial cells are threonine 696 (T696) and 
threonine 850 (T850). However, the mechanism of MLCP inhibition remains 
unclear. Several kinases have been reported to phosphorylate MYPT1 at one or 
MLC MLC~P Contraction Barrier failure
Relaxation 
Barrier stabilization
Ca2+/CM
MLCK
MLCP
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both of these sites. The major well-known kinase is Rock, which phosphorylates 
MYPT1 at both sites and inhibits its catalytic activity (Hartshorne, 1998; Fukata et 
al., 2001). Other kinases phosphorylating MYPT1 in a Ca2+-independent manner 
include zipper-interacting protein kinase (ZIPK) and the so called MYPT1-
associated kinase, which is highly homologous to ZIPK ( Hartshorne, 1998; 
Borman et al., 2002). Phosphorylation at T696 by Rock or ZIPK inhibits the activity 
of MLCP (Fukata et al., 2001; MacDonald et al., 2001; Borman et al., 2002). 
Accordingly, phosphorylation of T850 by Rock was shown to induce dissociation of 
MYPT1 from myosin and thus inactivation of MLCP (Velasco et al., 2002). These 
data confirm that the phosphorylation of MYPT1 plays an important role in the 
regulation of MLCP activity. 
 
1.3.5 Regulation of myosin light chain phosphatase activity by CPI-17 
 
Recent data, mainly from smooth muscle cells suggests an alternative 
mechanism for the regulation of the activity of MLCP holoenzyme. A small 17 kDa 
protein, the PKC-potentiated inhibitor 17-kDa protein (CPI-17), can directly interact 
with, and inactivate the catalytic subunit of MLCP (Murthy et al., 2003; Somlyo and 
Somlyo, 2003). CPI-17 is a soluble globular protein and was purified as a myosin 
phosphatase specific inhibitor from pig aorta (Eto et al., 1995). Phosphorylation of 
CPI-17 at threonine 38 (T38) was shown to enhance its inhibitory potency by more 
than 1000-fold (Eto et al., 2004). Several kinases such as PKCα/δ, PAK, ZIPK, 
integrin linked kinase (ILK), and Rock were shown to activate CPI-17 by 
phosphorylation at T38 (Koyama et al., 2000; MacDonald et al., 2001; Erdödi et 
al., 2003). Initially, CPI-17 was assumed to be present only in smooth muscle 
cells, but recently it was found in platelets (Watanabe et al., 2001), brain (Dubois 
et al., 2003) and also in endothelial cells of different origins (Kolosova et al., 2004). 
The phosphatase activity of purified MLCP towards phosphorylated MLC was 
completely inhibited in the presence of phosphorylated CPI-17 (Senba et al., 
1999). Agonists like histamine and thrombin, cause phosphorylation of CPI-17 in 
smooth muscle cells (Kitazawa et al., 2003), as well as in platelets (Watanabe et 
al., 2001) and endothelial cells (Kolosova et al., 2004).  
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1.4 cAMP and endothelial permeability 
 
cAMP is a well-known intracellular second messenger mediating 
stabilization of barrier function in isolated vessels as well as in cultured endothelial 
monolayers (Adamson et al., 1998; Stelzner et al., 1989; He et al., 2000). 
Consistently, activation of adenylyl cyclase via G-protein-coupled receptor (GPCR) 
agonists like, adenosine, prostacyclin, prostaglandin E2, and β-adrenergic 
agonists, direct activation of adenylyl cyclase (by FSK) as well as elevation of  
cytosolic cAMP concentration by blocking its degradation via phosphodiesterases, 
reduce endothelial hyperpermeability induced by inflammatory stimuli both in vitro 
and in in vivo (Carson et al., 1989; Langeler and van Hinsbergh, 1991; Suttorp et 
al., 1993; He and Curry, 1993; Fu et al., 2006). The effect of cAMP is fast and 
occurs in endothelial cells both under basal conditions as well as after exposure to 
inflammatory mediators. Its efficacy is independent on whether cAMP is elevated 
by activation of  adenylyl cyclase or by inhibition of cAMP-degrading 
phosphodiesterases (Van Hinsbergh, 2001).  
cAMP exerts its effect primarily through direct activation of PKA (Yuan, 
2002). It has been shown in endothelial cells that inhibition of PKA by 
overexpression of a specific peptide inhibitor of PKA (PKI) as well as by 
pharmacological inhibitors (e.g. Rp-cAMP), resulted in increased endothelial 
permeability (Lum et al., 1999; Liu et al., 2001). The barrier protective effects of 
cAMP towards inflammatory mediators were abolished in these cells. In an in situ 
study in intact frog and rat microvessels it was shown that inhibition of PKA leads 
to increased basal permeability (He et al., 2000). Liu and co-workers (2005) 
showed in cultured endothelial cells that inhibition of PKA leads to an increase in 
stress fiber formation and basal endothelial permeability. These studies 
demonstrate clearly that cAMP exerts its  effects on endothelial barrier function 
mainly by activating PKA.  
Recently, it has been shown that cAMP can also strengthen barrier function 
by PKA-independent mechanism. cAMP can activate the small GTPase Rap1 via 
activation of the exchange factor Epac1/2 (Cullere et al., 2005; Fukuhare et al., 
2005) leading to stabilization of adherens junctions. However, there is no evidence 
that activation of Epac causes dephosphorylation of MLC and  inactivation of the 
contractile machinery. 
  
13
 
The present study focuses on the molecular mechanism of the cAMP/PKA 
pathway which has been related to barrier stabilisation and protection via inhibition 
of the contractile machinery. A number of studies have shown that activation of 
PKA causes dephosphorylation of MLC (Moy et al., 1993), dissociation of F-actin 
from myosin (Langeler et al., 1991) and stabilization of cytoskeleton filaments 
(Hastie et al., 1997). Several studies have tried to elucidate the molecular 
mechanisms by which cAMP/PKA stabilizes the endothelial cytoskeleton. It has 
been proposed that cAMP/PKA inhibits the small GTPase RhoA and this in turn 
results in inhibition of phosphorylation of the regulatory MLC and thus activation 
state of the contractile machinery (Essler et al., 2000; Qiao et al., 2003). In an 
early study, Garcia and co-workers (1995) showed that cAMP/PKA activation 
causes MLCK phosphorylation and proposed that this might lead to MLCK 
inhibition. In a recent study Goeckeler and Wysolmerski (2005) clearly excluded 
that activation of cAMP/PKA pathway can lead to MLCK phosphorylation and 
inactivation.  
A number of studies in smooth muscle cells and few in endothelial cells 
(Birukov, 2003; Goeckeler and Wysolmerski, 2005) have shown that activation of 
cAMP/PKA pathway leads to activation of MLCP but a detailed molecular analysis 
has not yet been performed.  
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Fig 1.3 Regulation of myosin light chain phosphatase (MLCP). Thrombin, via 
protease-activated receptor-1 (PAR1), activates RhoA/Rock pathway. Rock 
inactivates myosin light chain phosphatase (MLCP) leading to increased myosin 
light chain (MLC) phosphorylation and contractile activation. Agonists like 
adenosine, via activation of adenosine A2 receptors activate adenylyl cyclase (AC) 
leading to increased production of cAMP and activation of protein kinase A (PKA). 
Activation of cAMP/PKA pathway can activate MLCP, which dephosphorylates 
MLC causing inactivation of  the contractile machinery. CPI-17 is an endogenous 
inhibitor of MLCP, activated by several kinases including PKC and Rock. 
 
1.5 Aims and objectives of the study 
 
The present study was conducted to elucidate the molecular mechanisms 
by which activation of the cAMP/PKA pathway leads to inactivation of the 
endothelial contractile machinery and protection of endothelial barrier function. 
Since previous studies in endothelial as well as smooth muscle cells demonstrated 
that cAMP/PKA exerts its main effect on contractile machinery via activation of 
MLCP, the present study was focused to analyze the molecular mechanism of 
MLCP activation via the cAMP/PKA signaling pathway. 
MLC MLC~P
Ca2+/CM
MLCK
MLCP
CPI-17
cAMP
PKA
AC
AgonistThrombin
RhoA/
Rock
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The study was performed using an established model of cultured 
monolayers of human umbilical vein endothelial cells (HUVEC). The following 
questions were addressed: 
 
• Does cAMP/PKA induce complex formation of the MLCP holoenzyme? 
Special emphasis was laid on analysis of recruitment of PP1 to MYPT1 and 
and the translocation of both to myosin. 
• Is this cAMP/PKA-induced MLCP holenzyme complex formation dependent 
on inhibition of RhoA/Rock pathway? 
• Does cAMP/PKA pathway cause inactivation of CPI-17, a specific inhibitor 
of PP1?  
• Does the RhoA/Rock pathway play a role in the cAMP/PKA-mediated effect 
on CPI-17?  
• Does inhibition of CPI-17 have any functional role in endothelial barrier 
failure caused by inflammatory mediators (e.g. thrombin)? 
 
The following experimental strategies were used to answer these questions. 
 
• Recruitment of MYPT1 and PP1 to myosin was analyzed by co-
immunoprecipitation analysis. 
• Activation of MLCP was analyzed by direct determination of phosphatase 
activity in co-immunoprecipitated complexes. 
• Activation of RhoA/Rock pathway was analyzed by pulldown assay and 
RhoA translocation to membranes by cell fractionation. 
• Interaction of CPI-17 with PP1 was analyzed by co-immunoprecipitation 
analysis and CPI-17 phosphorylation (i.e. activation) was analyzed by 
western blot analysis. 
• Macromolecule permeability across endothelial monolayers was used as a 
functional assay to evaluate the impact of CPI-17. in these experiments 
CPI-17 was downregulated by siRNA technique. 
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2 Methods 
 
2.1 Cell culture 
 
Isolation of human umbilical vein endothelial cells (HUVEC) 
 
Collagenase solution 
HBSS        x ml 
Collagenase II, 293 IU/mg (wt/vol)   0.025 % 
MgCl2        0.5 mM 
CaCl2        1.5 mM 
 
Endothelial cell culture medium 
Endothelial cell basal medium (PromoCell® ) supplemented with  
FCS (vol/vol)       10 % 
Endothelial cell growth supplement/Heparin (wt/vol) 0.4 %  
Hydrocortisone (wt/vol)     0.1 %  
bFGF (wt/vol)      1 ng/ml 
hEGF (wt/vol)      0.1 ng/ml 
Penicillin/streptomycin (vol/vol)    2 %  
 
Procedure. The study conforms with the principles outlined in the ‘’Declaration of 
Helsinki’’ (Cardiovascular Research 1997;35:2–3). Human umbilical vein 
endothelial cells (HUVEC) were isolated from freshly collected umbilical cords 
(from Gynecology Department, University Hospital Giessen) according to Jaffe et 
al., (1973) with some modifications. After cleaning, the umbilical vein was 
canulated and perfused with HBSS to remove traces of blood. Afterwards, the 
lumen of the vein was filled with collagenase solution and incubated for 20-30 
minutes at 37 °C. Afterwards, the collagenase solution, containing endothelial 
cells, was gently flushed from the vein by perfusion with 30 ml of HBSS containing 
3% (vol/vol) FCS, to inactivate the collagenase. The effluent was collected in a 50 
ml Falcon tube and centrifuged at 250 x g for 5 minutes at room temperature. The 
supernatant was removed and the cell pellet was resuspended in endothelial cell 
culture medium containing 0.1% gentamycin. The cell suspension was seeded on 
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3-4 primary cell-culture dishes and incubated at 37 °C with 5% CO2 for 2 hours. 
Thereafter, cells were washed with HBSS to remove erythrocytes, non-adherent 
cells, and cell debris and were incubated with cell culture medium containing 0.1% 
(vol/vol) gentamycin at 37 °C with 5% CO2. After 24 hours the medium was 
replaced with normal endothelial cell culture medium.  
 
Sub-culturing of HUVEC. Confluent monolayers of primary endothelial cells were 
trypsinized (5-7 days after isolation) in phosphate-buffered saline [PBS; 
composition in mM: 137 NaCl, 2.7 KCl, 1.7 KH2PO4, and 10 Na2HPO4; pH 7.4, 
supplemented with 0.05% (wt/vol) trypsin, and 0.02% (wt/vol) EDTA] and seeded 
at a density of 7 x 104 cells/cm2 on Transwell® filters (for permeability) or on cell 
culture dishes (for western blot analysis, immunoprecipitation and pulldown 
assay). Experiments were performed with confluent endothelial monolayers of 
either primary or passage 1, 3 days after seeding. 
 
2.2 General incubation conditions 
 
The basal medium used in incubations was HBSS supplemented with 1.3 
mM CaCl2, 1.2 mM MgCl2, and 2 % (vol/vol) FCS. After an initial equilibration 
period of 20 minutes, agents were added as indicated. Stock solutions of thrombin, 
Y27632 and PKI were prepared immediately before use with basal medium. Stock 
solutions of forskolin were prepared with dimethyl sulfoxide (DMSO). Appropriate 
volumes of these solutions were added to the cells yielding final solvent 
concentrations < 0.1% (vol/vol). The same final concentration of DMSO was 
included in all respective control experiments. Stock solutions of all other 
substances were prepared in basal medium (composition as described above). 
Appropriate volumes of these solutions were added to the cells. Identical additions 
of basal medium were included in all respective control experiments. 
In a set of pilot experiments, concentration-response relationships were 
determined to find the optimum effective concentration of the agents to be used in 
this study. The agents were applied in their optimum effective concentrations as 
follows: forskolin (5 µM), thrombin (0.2 IU/ml), PKI (100 µM), Y-27632 (10 µM). 
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2.3 Protein analysis 
 
Sample preparation 
 Endothelial cells were washed with HBSS and subsequently lysed in 150 µl 
2x SDS sample buffer (250 mM Tris/HCl; pH 6.8, 20% (vol/vol) glycerol, 4% 
(wt/vol) SDS, 1% (vol/vol) β-mercaptoethanol, 10 µM cantharidin, 0.001% (wt/vol) 
bromphenol blue, and 10 mM DTT added freshly before use). Subsequently, 50 
IU/ml Benzonase® and 2 mM MgCl2 was added and lysate was collected in a 1.5 
ml Eppendorf tube. Samples were denatured for 3 minutes at 95 °C and used 
immediately or stored at –20 °C. 
 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Resolving gel buffer: Tris/HCl; pH 8.8   120 mM  
Stacking gel buffer:   Tris/HCl; pH 6.8  120 mM  
 
10x Gel running buffer 
Tris      250 mM 
Glycine    2.0 M 
SDS (wt/vol)   10 % 
 
SDS gels 
The composition of gels of different percentages is given below: 
 
Gels Resolving gels 
Stacking 
gel 
Solutions   7.5 %    10 %    12.5 %   15 %     6 % 
Acrylamide 40% (wt/vol)   7.7 ml 10.2 ml 12.7 ml 15.3 ml   3.8 ml 
Bisacrylamide 2% (wt/vol)   4.2 ml   5.6 ml   7.0 ml   8.4 ml   2.0 ml 
Millipore water 17.7 ml 13.8 ml   9.8 ml   5.8 ml 17.5 ml 
Resolving gel buffer   9.5 ml   9.5 ml   9.5 ml   9.5 ml ------ 
Stacking gel buffer ------ ------ ------ ------   6.0 ml 
SDS 10% (wt/vol)   0.4 ml   0.4 ml   0.4 ml   0.4 ml 0.25 ml 
TEMED    30 µl   30 µl   30 µl   30 µl   20 µl 
APS 10% (wt/vol)   0.4 ml   0.4 ml   0.4 ml   0.4 ml 0.25 ml 
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Procedure. After cleaning the glass plates and spacers with water and ethanol, 
the gel apparatus was assembled and the resolving gel solution was poured (app. 
10 cm height), and layered with water. The gel was let to polymerize for 3-4 hours 
or overnight at room temperature.  
The layer of water was removed, the stacking gel solution was poured on 
top of the resolving gel, the comb was inserted and the stacking gel was let to 
polymerize for 1 hour at room temperature. After removing the comb 1x running 
gel buffer was added to the chamber and the wells were washed with a syringe. 
Protein samples were loaded into the wells and the gel was run overnight at 45 
volts. The run was stopped when bromophenol blue had passed through the gel. 
 
Electroblotting and immunodetection of proteins (Western Blot) 
Proteins separated by SDS-PAGE were transferred onto a nitrocellulose 
membrane by semi-dry blotting. Afterwards specific proteins were 
immunodetected using specific antibodies. 
 
Materials and solutions 
• Nitrocellulose transfer membrane, cut to the same dimensions as the gel  
• Six pieces of Whatman® 3 MM filter paper, cut to the same dimensions as 
the gel  
• Blotting chamber  
• Anode buffer 1: 0.3 M Tris/HCl; pH 10.4, 20% (vol/vol) methanol  
• Anode buffer 2: 30 mM Tris/HCl; pH 10.4, 20% (vol/vol) methanol  
• Cathode buffer: 25 mM Tris/HCl; pH 9.4, 40 mM 6-amino-n-hexanoic acid, 
20% (vol/vol) methanol  
• Millipore water 
 
Procedure. The blotting chamber was assembled as follows: Two sheets of filter 
paper (Whatman® 3MM) soaked in anode buffer 1, were placed in the centre of the 
graphite anode of the blotting chamber. On top of these sheets, two sheets of filter 
paper, soaked in anode buffer 2, were placed followed by nitrocellulose membrane 
equilibrated in anode buffer 2 for 10-15 minutes. After briefly equilibrating with 
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cathode buffer, the SDS-gel (devoid of stacking gel) was layered on top of the 
nitrocellulose membrane, avoiding air bubbles. Two sheets of filter paper, pre-
soaked in cathode buffer, were placed on top of the gel followed by the graphite 
cathode of the blotting chamber. Transfer was achieved by application of 0.8-0.9 
mA/cm2 current for approximately 2-2.5 hours. 
 
Ponceau staining of proteins 
To estimate the efficiency of protein transfer after blotting, the membrane 
was stained with ponceau S. This stain is reversible and produces pink bands on a 
light background. The nitrocellulose membrane was washed with Millipore water 
for 1 minute, incubated in Ponceau-S solution for 2-3 minutes with constant 
shaking at room temperature. Subsequently the membrane was destained by 
washing in Millipore water to the desired contrast and photographed. To remove 
the stain completely, the membrane was washed with TBST (1x TBS plus 0.1% 
tween 20) under constant shaking. 
 
Immunodetection of proteins 
 
Solutions
10x Tris-buffered saline (TBS) 
Tris/HCl (pH 7.4)  100 mM 
NaCl    1.6 M 
 
TBS Tween (TBST) 
1x TBS    
0.1% (vol/vol) Tween 20 
  
Blocking-buffer and antibody-dilution buffer 
3% (wt/vol) BSA in 1x TBST (BSA) or  
5% (wt/vol) non-fat dried milk powder in 1x TBST (Milk) 
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Primary Antibodies 
Antibody      Dilution  Dilution buffer 
CPI-17 (Rabbit IgG, polyclonal)   1:1000  Milk 
Phospho CPI-17 (Rabbit IgG, polyclonal) 1:1000  BSA 
MLC (Clone MY-21, mouse IgM, monoclonal) 1:2000  Milk 
MYPT1 (Sheep IgG, polyclonal)   1:1000  Milk 
Phospho MYPT696 (Rabbit IgG, polyclonal) 1:1000  BSA 
Phospho MYPT850 (Rabbit IgG, polyclonal) 1:1000  BSA 
PP1δ (Rabbit IgG, polyclonal)   1:1000  BSA 
RhoA (Mouse IgG, monoclonal)   1:1000  BSA 
Vinculin (Clone hVIN-1, mouse IgG,  
monoclonal)      1:1000  BSA 
 
Secondary  antibodies, horseradish peroxidase (HRP)-labeled 
Antibody      Dilution  Dilution buffer 
Anti-rabbit IgG     1:1000  BSA or Milk  
Anti-mouse IgG     1:1000  BSA or Milk 
Anti-mouse IgM     1:2000  BSA or Milk 
Anti-sheep IgG     1:1000  BSA or Milk 
 
Procedure. After a brief washing with Millipore water and TBST, the membrane 
was blocked with either 5% (wt/vol) non-fat milk powder or 3% (wt/vol) BSA in 
TBST for 2 hours at room temperature. After blocking, the membrane was 
incubated with primary antibody overnight at 4°C. The membrane was then 
washed with TBST 3-4 times for 5-10 minutes each at room temperature and 
incubated with secondary antibody for 1 hour at room temperature. The membrane 
was then washed with TBST 3-4 times for 10-15 minutes (each) and was then 
incubated with enhanced chemiluminescence (ECL) solution (30 seconds to 1 
minute) and the luminescence was detected and recorded with Bio-Rad Quantity 
One gel documentation system. 
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2.4 Determination of MLC phosphorylation  
 
The phosphorylation of MLC was determined by glycerol-urea polyacrylamide gel 
electrophoresis and Western blot analysis (Persechini et al., 1986). This procedure 
allows separation of non-phosphorylated from phosphorylated MLC protein, the 
latter of which migrates more rapidly. 
 
Urea-glycerol gel 
Following solutions were used to make 6 small gels: 
Glycerol (87%)    20.70 ml 
Acrylamide solution 40% (wt/vol)  11.25 ml 
Bisacylamide solution 2% (wt/vol) 9.50 ml 
Urea-gel buffer    3.80 ml 
To remove air bubbles, the solution was degassed for 10 minutes with a water 
vacuum pump. 
TEMED     7.10 µl 
APS 10% (wt/vol)    200 µl 
 
Urea-gel buffer    
Tris/HCl     240 mM   
Glycine     276 mM   
Adjust pH to 8.8  
Anode buffer  
Urea-gel buffer    83 ml 
Millipore water    917 ml 
 
Cathode buffer 
Anode buffer     450 ml 
DTT      2.3 mM 
Sodium thioglycolate    2.4 mM 
 
Procedure. Experimental incubations of cultures were terminated by a rapid 
removal of the medium and addition of 10% (wt/vol) ice-cold trichloroacetic acid 
and incubation on ice for 30-60 minutes. Precipitated proteins were transferred 
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into 1.5 ml Eppendorf tubes and centrifugated at 10,000 x g for 10 minutes at 4 °C. 
Sediments were washed 2-3 times with diethylether. After evaporation of 
diethylether, sediments were suspended in 30 µl lysis buffer (8.8 M urea, 60 mM 
imidazole, 23 mM glycine, 20 mM Tris/HCl; pH 8.8, 10 mM DTT, 5 mM sodium 
thioglycolate, 10 µM cantheridin, 0.001 % (wt/vol) bromophenol  blue). Before 
loading the lysates, the gels were pre-run at 400 V for 1 h. Approximately 20-40 of 
µg protein per lane was loaded on 10% urea-glycerol polyacrylamide gels and 
allowed to run at 400 V and 18 °C for 80 minutes. Separated proteins were blotted 
on nitrocellulose membranes (0.2 µm) and incubated as described under section 
2.3, with an anti-MLC antibody (1:2000) over night, followed by incubation of HRP-
labeled anti-mouse IgM antibody (1:2000) for 1 hour at room temperature. 
Luminescence was detected and recorded with Bio-Rad Quantity One gel 
documentation system. The percentage of MLC phosphorylation (expressed as % 
of total MLC) was calculated from densitometrical values of non- (MLC), mono- 
(MLC~P), and diphosphorylated MLC (MLC~PP) as follows: 
 
     (2 x MLC ~ PP) + MLC ~ P 
MLC phosphorylation (%) =     --------------------------------------------   x 100   
Total MLC 
 
As all MLC can become diphosphorylated, MLC phosphorylation (%) varies 
between 0 and 200 %. 
 
2.5 Co-immunoprecipitation of proteins 
 
Preparation of beads. Protein G-coated magnetic beads (6 µl beads suspension 
for approximately 1 mg of total cell lysate) were washed 3-4 times with 0.1 M 
sodium phosphate buffer (composition: 80 mM Na2HPO4, 20 mM NaH2PO4; pH 
7.4) and incubated with the respective antibody (4-5 µg for 1 mg total cell lysate) 
overnight at 4 °C with end-over-end rotation. Afterwards the beads were washed 
3-4 times with 0.1 M sodium phosphate buffer containing 0.1 % (vol/vol) Tween 20 
and stored in 50 µl of PBS. 
 
Immunoprecipitation. Confluent endothelial monolayers cultured on a 10-cm cell 
culture dish were stimulated as indicated in the text. Cells were incubated with 600 
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µl lysis buffer containing 50 mM Tris/HCl; pH 7.4, 150 mM NaCl, 1% (vol/vol) 
Triton X-100, 0.5% (vol/vol) NP-40, 1 mM EDTA, 1 mM EGTA, 20 mM NaF, 1.5 
mM Na-orthovanadate, 10 mM DTT, 0.5 mM PMSF, and Complete® protease 
inhibitor cocktail, for 10 minutes on ice and subsequently harvested by scraping 
with a rubber policeman and lysed by passing through a 26G needle (4-5 times). 
Lysates were cleared by centrifugation at 1,000 x g for 5 minutes at 4 °C. The 
supernatant was transferred to another tube and incubated with the respective 
antibodies pre-immobilized on protein G-coated magnetic beads for 1.5 hours at 4 
°C with end-over-end rotation. After incubation, beads were washed three times 
with PBS containing 0.1 % (vol/vol) Tween 20. The beads were collected and the 
bound proteins were eluted in 2x SDS sample buffer and analyzed by western blot 
analysis. 
 
2.6 Protein phosphatase assay 
 
Preparation of [32P]-labeled substrate. [32P]-labeled phosphorylase-a was 
prepared according to Essler et al., (1998) with some modifications. Briefly, 
phosphorylase-b (5 mg/ml) and phosphorylase-kinase (200 IU/ml) were incubated 
in a 2 ml incubation mixture (composition: 20 mM MgCl2, 31 mM β-
mercaptoethanol, 0.5 mg/ml BSA, 1 mM CaCl2, 1 mM ATP, 1 mCi γ-[32P]-ATP, and 
50 mM Tris/HCl; pH 7.4) for 2.5 hours at 30 °C. The radioactive-labeled 
phosphorylase-a was precipitated by addition of 2 volumes of ice-cold saturated 
ammonium sulfate solution. The tube was incubated for 20 minutes on ice and  
centrifuged for 30 minutes at 12,000 x g at 4 °C. The precipitate was solubilized in 
2 ml dialysis buffer (10 mM Tris/HCl; pH 7.4, 1 mM EDTA) dialyzed two times at 
room temperature against 2 liter dialysis buffer and finally stored at 4 °C. 
Radioactive labeling was verified by measuring the product in a liquid scintillation 
counter (Tri-Carb 1600 TR liquid scintillation counter).   
 
Determination of protein phosphatase activity. Protein phosphatase activity 
was determined according to Neumann et al. (1991). For determination of protein 
phosphatase activity of MLCP, the holoenzyme was immunoprecipitated using an 
anti-MYPT1 specific antibody pre-immobilized on protein G-coated magnetic 
beads (see section 2.5). Aliquots were preincubated in a total volume of 30 µl for 
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10 minutes at 30 °C in the presence or absence of 5 nM okadaic acid, a 
concentration inhibiting protein phosphatase 2A, or 0.5 µM human recombinant 
inhibitor 2 (rec. I-2), a specific inhibitor of PP1. The reaction was started by 
addition of 20 µl [32P]-labeled phosphorylase-a in an incubation mixture containing 
50 mM Tris/HCl; pH 7.4, 12.5 mM caffeine, 0.25 mM EDTA, 1.25 mM MnCl2, 
0.25% (vol/vol) β-mercaptoethanol. After incubation for 20 minutes at 30 °C, the 
reaction was terminated on ice by addition of 20 µl of 50% (wt/vol) ice-cold 
trichloroacetic acid (TCA) and 30 µl of 2% (wt/vol) bovine serum albumin (BSA). 
After 15 minutes on ice, the suspension was centrifuged at 12,000 x g for 5 
minutes at 4 °C. 70 µl of the supernatant was measured in a liquid scintillation 
counter. Reactions were carried out in duplicate or triplicate. To ensure linear rates 
of dephosphorylation, the extent of dephosphorylation of [32P]-labeled 
phosphorylase-a was restricted to <25%.  
 
2.7 Detection of activated RhoA  
 
   The assay was performed according to the manufacturer’s instructions 
using the Rho binding domain of rhotekin (Rhotekin-RBD) to specifically bind and 
isolate activated GTP-bound RhoA.  
 
Procedure. Endothelial cells were stimulated with FSK, thrombin, or combination 
of both. Afterwards the cells were washed with ice-cold PBS and incubated with 
600 µl of lysis buffer (25 mM Hepes; pH 7.4, 150 mM NaCl, 5 mM MgCl2, 1 mM 
EDTA, 10 mM NaF, 2 mM Na-orthovanadate, 5 mM DTT, 0.5 mM PMSF, 2% 
(vol/vol) glycerol, 0.5% (vol/vol) Triton X-100, and Complete® protease inhibitor 
cocktail. The cells harvested by scraping with a rubber policeman and lysed by 
passing through a 26G needle (4-5 times). Lysates were cleared by centrifugation 
at 14,000 x g for 5 minutes at 4 °C. The supernatant was transferred into another 
tube and incubated with 10 µg of Rhotekin-RBD beads at 4 °C for 40 minutes. The 
beads were washed four times with wash buffer (25 mM Tris/HCl; pH 7.4, 150 mM 
NaCl, 10 mM MgCl2, 1% (vol/vol) Triton X-100, 0.5 mM PMSF and Complete® 
protease inhibitor cocktail, heated to 95 °C for 5 minutes with 40µl of 2x SDS 
sample buffer (see section 2.3) and loaded on a 12.5% SDS-PAGE. RhoA protein 
was detected by western blot analysis using anti-RhoA mouse monoclonal 
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antibody. RhoA activation was estimated by correlation of isolated GTP-bound 
RhoA to total amount of RhoA in cell lysates.  
 
2.8 Determination of RhoA translocation 
 
 Activation of RhoA leads to its translocation to the cell membrane (Takaishi 
et al., 1996), so RhoA translocation to membrane was also determined by cell 
fractionation. After stimulation the cells were washed briefly with ice-cold PBS and 
then incubated with lysis buffer (5 mM Tris/HCl; pH 7.4, 250 mM sucrose, 5 mM 
NaCl, 1 mM MgCl2, 5 mM EDTA, 10 mM DTT, 0.5 mM PMSF, and Complete® 
protease inhibitor cocktail, for 10 minutes on ice. Subsequently, cells were 
collected with a rubber policeman and lysed by passing through a 26G needle (4-5 
times). Cell debris and nuclei were removed by centrifugation at 1000 x g for 5 
minutes at 4 °C to clear the lysate. Afterwards, the supernatant was centrifuged at 
100,000 x g for 30 minutes at 4 °C. The pellet was washed three times with lysis 
buffer, dissolved in 2xSDS-sample buffer and analyzed by SDS-PAGE and 
western blot analysis. 
 
2.9 Measurement of endothelial monolayer permeability  
 
The endothelial permeability was measured according to Noll et al. (1999) 
using a two compartment system. The luminal and abluminal compartments were 
separated by a porous membrane (pore size 0.4 µm). The cells were cultured on 
the membrane (Transwell®) filters until confluent. HBSS [supplemented with 1.3 
mM CaCl2, 1.2 mM MgCl2, and 2% (vol/vol) fetal calf serum (FCS)] was added in 
both compartments as basal medium. The luminal compartment contained 2.5 ml 
the while the abluminal compartment contained 9.5 ml of this medium. There was 
no difference in hydrostatic pressure between the luminal and abluminal 
compartment. In the luminal compartment, trypan blue-labeled albumin was added 
in a final concentration of 60 µM. The diffusion of trypan blue-labeled albumin from 
the luminal to the abluminal compartment was measured with a spectrophotometer 
(Specord 10, Zeiss Jena, Germany) continuously every minute. To avoid 
measurement artefacts, two-wavelength measurement mode was used (trypan 
blue 600 nm versus control 720 nm). 
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The albumin flux (F, measured in mol/(sec x cm2) through endothelial monolayer 
area (S) was calculated as the increase in albumin concentration (d[A]2) during the 
time interval (dt) in the abluminal compartment with the volume (V) as follows: 
 
d[A]2 / dt x V 
F = ------------------------   (1) 
        S 
 
The combined permeability coefficient (P [cm/sec]) of both endothelial cell 
monolayer and filter membrane was calculated as: 
 
     F 
P = ------------------------   (2) 
([A]1 – [A]2) 
 
Where [A]1 and [A]2 are the albumin concentrations in luminal and abluminal 
compartments, respectively.  
 
2.10 Downregulation of endogenous CPI-17  
 
To reduce the content of CPI-17, endothelial cells were treated with CPI-17-
specific siRNA duplex. siRNA was ordered from QIAGEN in purified, desalted, 2'-
deprotected duplex form. Duplex of sense 5'-ACCUGUCGAGGACUUCAUCdTdT-
3' and antisense 5'-GAUGAAGUCCUCGACAGGUdTdT-3' siRNA was used as 
described by Kolosova et al. (2004). Nonspecific RNA duplex was used as a 
control treatment. Endothelial cells were seeded on 35-mm cell culture dishes (for 
western blotting), and on Transwell® filters (for permeability experiments). When 
70% confluence was reached siRNA (100 nM) was transfected with FuGENE® 6 
transfection reagent. Experiments were performed 48 hours after the incubations. 
Downregulation of CPI-17 was determined by western blot analysis. 
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Transfection  
Transfection was carried out with 100 nM of siRNA.  Calculations for 7 wells (6 
well culture dish) are given below:  
Two mixtures (siRNA and FuGENE® 6) were prepared in two different tubes.  
Tube 1.  35 µl of 40 µM siRNA was mixed with 315 µl of serum-free medium. 
Tube 2. 6 µl of FuGENE® 6 was mixed with 344 µl of serum-free medium. 
 
The content of Tube 1 were added to Tube 2 and mixed by vortexing for 10 
seconds and were incubated for 25 minutes at room temperature. Afterwards, the 
mixture was added to 6.3 ml of serum free medium and mixed properly. 
Subsequently, 1 ml of this mixture was added to each well already containing 1 ml 
of serum free medium. Cells were then incubated at 37 ºC in 5% CO
2 
for 12 hours. 
Afterwards the transfection medium was replaced with the normal medium. After 
48 hours, respective experiments were performed. 
 
2.11 Statistical analysis  
 
Data are given as means + S.D. of 5 experiments using independent cell 
preparations. The comparison of means between groups was performed by one-
way analysis of variance (ANOVA) followed by a Student-Newman-Keuls post-hoc 
test. Changes in parameters within the same group were assessed by multiple 
ANOVA analysis. Probability (P) values of less than 0.05 were considered 
significant (P< 0.05). 
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3 Results  
 
3.1 Effect of FSK on endothelial permeability 
 In the first instance, experiments were performed to confirm that, in the 
endothelial cell culture model used, activation of adenylyl cyclase can reduce 
basal endothelial permeability as well as thrombin-induced hyperpermeability, and 
that this effect is associated with reduction in the contractile activity of endothelial 
cells. Under control conditions endothelial monolayers exhibited a stable 
permeability for albumin (Fig. 3.1). When 5 µM FSK was added, to directly activate 
the adenylyl cyclase, permeability rapidly declined. Conversely, permeability 
rapidly rose when thrombin (0.2 IU/ml) was applied. Simultaneous addition of both 
agents reduced the thrombin effect nearly to basal level. To test whether the effect 
of FSK on thrombin-induced hyperpermeability is mediated by PKA, endothelial 
cells were incubated for 30 minutes in the presence of 100 µM PKI, a specific cell 
permeable peptide inhibitor of PKA. As shown in Fig. 3.1, PKI abolished the effect 
of FSK on thrombin-induced hyperpermeability. 
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Fig. 3.1   Effects of forskolin (FSK), thrombin (Thr), and FSK plus Thr on albumin 
permeability of human umbilical vein endothelial monolayers. Endothelial cells 
were exposed to 5 µM FSK, 0.2 IU/ml Thr, FSK plus Thr or vehicle (Control). In a 
set of experiments cells were incubated with 100 µM PKI (a specific peptide 
inhibitor of PKA) for 30 minutes before FSK plus Thr was added (PKI+FSK+Thr). 
Data are means ± SD of 5 separate experiments with independent cell 
preparations. As indicated at time points between 2.5 and 30 minutes permeability 
is significantly different. P < 0.05: ∗FSK vs. Control; #FSK plus Thr vs. Thr alone. 
PKI plus FSK plus Thr is not significantly different from Thr alone. 
 
 
3.2 Effect of FSK on MLC phosphorylation 
Since MLC phosphorylation controls the activation of the endothelial 
contractile machinery, this parameter of contractile activation was analyzed (Fig. 
3.2). FSK caused a decrease and thrombin an increase in MLC phosphorylation. 
The combined addition of FSK plus thrombin abolished the thrombin effect and 
reduced MLC phosphorylation below basal level. To test whether the effect of FSK 
on thrombin-induced MLC phosphorylation is mediated by PKA, endothelial cells 
were incubated for 30 minutes in the presence of 100 µM of PKA inhibitor (PKI). 
As shown in Fig. 3.2, PKI abolished the effect of FSK on thrombin-induced MLC 
phosphorylation. 
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Fig. 3.2   Effects of forskolin (FSK), thrombin (Thr),  FSK plus Thr and calyculin A 
on endothelial MLC phosphorylation. (A) Representative western blots of MLC 
phosphorylation. Endothelial cells were exposed to 5 µM FSK, 0.2 IU/ml Thr, FSK 
plus Thr or vehicle (C; control) for 10 minutes. In a set of experiments cells were 
incubated with 100 µM PKI (a specific peptide inhibitor of PKA) for 30 minutes 
before FSK plus Thr was added (PKI+FSK+Thr), as indicated. As a positive 
control 1 nM Calyculin A (Caly), a protein phosphatase inhibitor, was added for 20 
minutes. The bands represent, from top to bottom, non- (MLC), mono- (MLC~P), 
and diphosphorylated MLC (MLC~PP), respectively. (B) Densitometric analysis of 
the western blots shown in A. As all MLC can become diphosphorylated, MLC 
phosphorylation varies between 0 and 200 %. Data are means ± SD of 5 separate 
experiments with independent cell preparations. P < 0.05: ∗FSK vs. Control; #FSK 
plus Thr vs. Thr alone. n.s: not significantly different.  
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 MLC phosphorylation is mediated via RhoA/Rock pathway in endothelial 
cells. Here it was analyzed whether cAMP/PKA causes dephosphorylation of MLC 
via inhibition of the RhoA/Rock pathway. For that reason RhoA/Rock pathway was 
blocked by Y27632, a specific inhibitor of Rock. At optimum concentration (10 µM), 
Y27632 reduced MLC phosphorylation to 20 ± 6 % in 10 minutes (Fig. 3.3). 
Addition of 20 µM Y27632 could not further reduce MLC phosphorylation. 
Simultaneous addition of FSK plus Y27632 (10 µM) reduced MLC phosphorylation 
to 3 ± 5% . These data indicate that even under basal conditions the level of MLC 
phosphorylation is influenced by Rock pathway and is reduced by cAMP/PKA at 
least in part by a RhoA/Rock-independent pathway. 
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Fig. 3.3   Effects of forskolin (FSK), Y27632 (Y), or FSK plus Y on endothelial MLC 
phosphorylation. (A) Representative western blots of MLC. Endothelial cells were 
exposed to FSK (5 µM), Y (10 or 20 µM), FSK plus Y (10 µM) or vehicle (C; 
control) for 10 minutes. The bands represent, from top to bottom, non- (MLC), 
mono- (MLC~P), and diphosphorylated MLC (MLC~PP), respectively. (B) 
Densitometric analysis of the western blots  shown in A. Data are means ± SD of 5 
separate experiments with independent cell preparations. ∗P < 0.05, #P < 0.05.  
n.s.:  not significantly different. 
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3.3 Effect of FSK on MLC phosphatase complex formation and activity 
 Dephosphorylation of MLC may result either from inactivation of MLCK or 
activation of MLCP. Previously it has been shown (Bindewald et al., 2004) that 
stimulation of cAMP/PKA pathway can attenuate MLCK activity in endothelial cells. 
However, this attenuation can not explain the reduction of MLC phosphorylation 
observed. This concept is supported by recent data from Goeckeler and 
Wysolmerski (2005) who reported that cAMP/PKA has no significant effect on 
MLCK activity. Therefore, in the present study the effect of cAMP/PKA on MLCP 
activation was analyzed. The activation of MLCP requires that the PP1 catalytic 
subunit interacts with MYPT1, the myosin phosphatase targeting subunit, leading 
to formation of the MLCP holoenzyme complex. This MLCP holoenzyme complex 
has higher affinity to phosphorylated MLC. To analyze whether FSK induces 
MLCP complex formation, recruitment of PP1 and MYPT1 to myosin, was 
determined by immunoprecipitation using either a MYPT1 or a PP1-specific 
antibody. In the first step, PP1 and MLC were co-immunoprecipitated with MYPT1 
in non-stimulated cells, indicating that an MLCP complex is already formed under 
basal conditions in endothelial cells (Fig. 3.4A, C). Exposure of endothelial cells to 
FSK increased the recruitment of PP1 and MLC to MYPT1 by 2.4 ± 0.5 and 
4.3 ± 0.6-fold, respectively. This recruitment of PP1 lead to a 2-fold increase in 
phosphatase activity of the immunoprecipitated MLCP complex (Fig. 3.4B). 
Phosphatase activity of the immunoprecipitates, both of control and FSK-treated, 
was completely blocked by addition of 0.5 µM recombinant inhibitor 2 (rec. I-2), a 
PP1 specific inhibitor, indicating that the phosphatase activity is solely due to PP1. 
In the second step, the assembly of MLCP complex was confirmed by 
immunoprecipitation using a PP1 specific antibody. As shown in Fig. 3.4D, under 
basal conditions MLCP complex is already formed and FSK induced the 
recruitment of MYPT1 and MLC to the catalytic subunit PP1.  
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Fig. 3.4   Effect of forskolin (FSK) on MLCP complex assembly and activity of the 
immunoprecipitated phosphatase complexes. Endothelial cells were exposed to 
5µM FSK or vehicle (C; control) for 10 minutes. MLCP was immunoprecipitated 
with an anti-MYPT1 antibody coupled to protein G-coated magnetic beads and 
analyzed by western blot analysis. Phosphatase activity of the immunoprecipitates 
was determined by phosphatase assay. (A) Densitometric analysis of the western 
blots shown in C.  PP1 and MLC relative to MYPT1 are given as x-fold increase 
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compared to control. The ratio of control was set to 1. (B) Phosphatase activity of 
the immunoprecipitated MCLP complex, measured in the absence or presence of 
0.5 µM recombinant inhibitor 2 (rec. I-2). The mean phosphatase activity of the 
control cells was set to 1. (C) Representative western blots of MYPT1, PP1 and 
MLC co-immunoprecipitated with MYPT1. (D) Representative western blots of 
PP1, MYPT1, and MLC co-immunoprecipitated with PP1. PP1 was 
immunoprecipitated with an anti-PP1 antibody coupled to protein G-coated 
magnetic beads. Data are means ± SD of 5 separate experiments of independent 
cell preparations. ∗P < 0.05, FSK vs. control; n.s.: not significantly different. 
 
 
 
To analyze whether RhoA/Rock is involved in cAMP/PKA-induced MLCP 
complex formation, endothelial cells were exposed to 10 µM Y27632, a 
concentration with maximum effect on MLC dephosphorylation (see Fig. 3.3). The 
assembly of MLCP complex was determined by co-immunoprecipitation using the 
same MYPT1 specific antibody as in the previous set of experiments. If 
cAMP/PKA mediates the formation of the MLCP complex via inhibition of 
RhoA/Rock, then Rock inhibition should influence MLCP complex formation. 
However, Y27632 did not lead to an increase in PP1 recruitment to MYPT1. It was 
found that Y27632 does not affect FSK-induced recruitment of PP1 to MYPT1. 
These data indicate that inhibition of RhoA/Rock is not involved in cAMP/PKA-
induced MLCP complex formation.  
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Fig. 3.5   Effect of forskolin (FSK), Y27632 (Y) or FSK plus Y on MLCP complex 
formation. Endothelial cells were exposed to FSK (5 µM), Y (10 µM), FSK plus Y 
for 10 minutes or vehicle treated (C; control). MYPT1 was immunoprecipitated 
using an anti-MYPT1 antibody coupled to protein G-coated magnetic beads. Co-
immunoprecipitation of MYPT1 and PP1 was analyzed by western blot analysis. 
(A) Representative western blots of MYPT1 and PP1 co-immunoprecipitated with 
anti-MYPT1 antibody. (B) Densitometric analysis of western blots shown in A. PP1 
relative to MYPT1 is given as x-fold increase compared to control. The ratio of 
control was set to 1. Data are means ± SD of 5 separate experiments of 
independent cell preparations. ∗P < 0.05, FSK plus Y or FSK alone vs Control. 
n.s.: not significantly different. 
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3.4 Effect of FSK on MYPT1 phosphorylation  
There is evidence that the affinity of the MLCP complex to phosphorylated 
MLC is controlled by phosphorylation of MYPT1 at T850. Here it was studied 
whether activation of cAMP/PKA signaling can affect MYPT1 phosphorylation and 
whether this signaling mechanism can counteract thrombin-induced MYPT1 
phosphorylation. Under control conditions exposure of endothelial cells to FSK 
reduced MYPT1 phosphorylation at T850 to half of the basal level (Fig. 3.6). 
Addition of thrombin for 10 minutes caused a 2.5-fold increase in MYPT1 
phosphorylation. Simultaneous addition of FSK plus thrombin abolished the 
thrombin-induced MYPT1 phosphorylation. 
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Fig. 3.6 Effect of forskolin (FSK), thrombin (Thr) or FSK plus Thr on MYPT1 
phosphorylation at threonine 850 (T850). Endothelial cells were exposed to FSK 
(5µM), thrombin (0.2 IU/ml), FSK plus Thr or vehicle (C; control) for 10 minutes. 
(A) Representative western blots with an anti-phospho-T850 MYPT1 and anti-
vinculin antibody. (B) Densitometric analysis of western blots shown in A. MYPT1 
phosphorylation relative to vinculin is given as % increase compared to control. 
The ratio of control was set to 100%. Data are means ± SD of 5 separate 
experiments of independent cell preparations. ∗P < 0.05. 
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3.5 Effect of FSK on RhoA translocation 
Activation of RhoA/Rock pathway requires that RhoA is translocated to the 
plasma membrane. To analyze whether FSK affects translocation of RhoA, 
membrane fractions were prepared and analyzed by western blot analysis. 
Stimulation of endothelial cells with FSK reduced the amount of RhoA in the 
membrane fraction to half of the control value (Fig. 3.7). Thrombin increased the 
translocation of RhoA to membranes by 1.8-fold, compared to control. This 
thrombin effect was abolished when cells were incubated in the presence of FSK 
plus thrombin. 
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Fig. 3.7 Effect of forskolin (FSK), thrombin (Thr) or FSK plus Thr on RhoA 
translocation. Cells were treated with FSK (5 µM), thrombin (0.2 IU/ml), FSK plus 
thrombin or vehicle (C; control) for 10 minutes. Membrane fractions from equal 
amounts of cell lysates were isolated and analyzed by western blot analysis using 
an anti-RhoA antibody. (A) Representative western blots of membrane fraction 
and whole cell lysate with an anti-RhoA antibody (B) Densitometric analysis of 
western blots shown in A. RhoA in the membrane fraction relative to total RhoA is 
given as x-fold increase compared to control. The ratio of control was set to1. Data 
are means ± SD of 5 separate experiments of independent cell preparation. ∗P < 
0.05. 
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3.6 Effect of forskolin on CPI-17 phosphorylation and co-
immunoprecipitation with PP1 
The activity of the catalytic subunit PP1 is regulated by an endogenous 
inhibitor CPI-17, which interacts and inactivates PP1 when phosphorylated at 
threonine 38 (T38). Here the influence of FSK and thrombin on CPI-17/PP1 
interaction and PP1 activity were analyzed. Therefore, PP1 was 
immunoprecipitated by using an anti-PP1 antibody coupled to magnetic beads. 
The immunoprecipitated proteins were resolved by SDS-PAGE and analyzed by  
western blot analysis. Under basal conditions CPI-17 is co-immunoprecipitated 
with PP1 (Fig. 3.8). Exposure of endothelial cells to FSK reduced co-
immunoprecipitation of CPI-17 with PP1 by 0.5-fold within 10 minutes. This 
reduction was accompanied by 60% increase in PP1 activity corresponding to a 2-
fold increase in PP1 activity in MYPT1 co-immunoprecipitates. Thrombin caused a 
1.7-fold increase of CPI-17 with PP1 immunoprecipitates and a 40% reduction in 
PP1 activity. Simultaneous addition of FSK plus thrombin completely abolished 
thrombin-induced complex formation and PP1 inhibition. Phosphatase activity of 
the immunoprecipitates, both of control and FSK-treated, was completely blocked 
by addition of 0.5 µM rec. I-2, a PP1 specific inhibitor, indicating that the 
phosphatase activity is solely due to PP1. 
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Fig. 3.8 Effect of forskolin (FSK), thrombin (Thr) or FSK plus Thr on CPI-17/PP1 
complex and activity of the co-immunoprecipitaed complexes. Endothelial cells 
were treated with FSK (5 µM), Thr (0.2 IU/ml), FSK plus Thr or vehicle (C; control) 
for 10 minutes and PP1 was co-immunoprecipitated using anti-PP1 antibody 
coupled to protein G-coated magnetic beads and analyzed by western blot 
analysis. Phosphatase activity of the immunoprecipitated complex was measured 
by phosphatase assay. (A) Representative western blots of PP1 and CPI-17 co-
immunoprecipitated with PP1. (B). Densometric analysis of western blots shown in 
A. CPI-17 relative to PP1 are given as x-fold increase compared to control. The 
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ratio of control was set to 1. (C). Phosphatase activity of immunoprecipitated 
phosphatase, measured in the absence or presence of 0.5 µM recombinant 
inhibitor 2 (rec. I-2). PP1 activity is given as % increase compared to control. The 
mean of PP1 activity of control was set to 100%. Data are means ± SD of 5 
separate experiments with independent cell preparations. ∗P < 0.05. n.s.: not 
significantly different. 
 
 
 
It is reported that the interaction of CPI-17 with PP1 is controlled by its 
phosphorylation at T38. Therefore it was analyzed whether the reduction of co-
immunoprecipitation of CPI-17 with PP1 was accompanied by a decrease of CPI-
17 phosphorylation. In accordance with the reduction in co-immunoprecipitation of 
CPI-17 with PP1, FSK caused a dephosphorylation of CPI-17 at T38 by 50% 
compared to control within 10 minutes (Fig. 3.9), whereas thrombin increased CPI-
17 phosphorylation to 150%. FSK abrogates this thrombin effect on CPI-17 
phosphorylation. 
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Fig. 3.9 Effect of forskolin (FSK), thrombin (Thr) or FSK plus Thr on CPI-17 
phosphorylation at threonine 38 (T38). Endothelial cells were treated with FSK 
(5µM), Thr (0.2 U/ml), FSK plus Thr or vehicle (C; control) for 10 minutes. (A) 
Representative western blots with an anti-phospho-T38 CPI-17 and pan-specific 
anti-CPI-17 antibody. (B) Densitometric analysis of western blots shown in A. CPI-
17 phosphorylation relative to total CPI-17 is given as % of control. The ratio of 
control was set to 100%. Data are means ± SD of 5 separate experiments with 
independent cell preparations. ∗P < 0.05. 
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 Furthermore it was analyzed whether FSK-induced dephosphorylation of 
CPI-17 is due to an inhibition of RhoA/Rock pathway. For that reason endothelial 
cells were incubated in presence of Y27632 to inhibit Rock. At 10 µM, an optimum 
concentration to obtain maximum effects on MLC dephosphorylation, it reduced 
CPI-17 phosphorylation to approximately 50% after 10 minutes. (Fig. 3.10). 
Addition of 20 µM Y27632 did not further reduce CPI-17 phosphorylation 
significantly. However, simultaneous addition of FSK plus 10 µM Y27632 reduced 
CPI-17 phosphorylation to almost zero.  
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Fig. 3.10   Effects of forskolin (FSK), Y27632 (Y), or FSK plus Y on endothelial 
CPI-17 phosphorylation. Endothelial cells were exposed to FSK (5 µM), Y (10 or 
20 µM), FSK plus Y (10 µM) or vehicle (C; control). (A) Representative western 
blots with an anti-phospho-T38 CPI-17 and anti-vinculin antibody. (B) 
Densitometric analysis of western blots shown in A. CPI-17 phosphorylation 
relative to vinculin is given as % of control. The ratio of control was set to 100%. 
Data are means ± SD of 5 separate experiments with independent cell 
preparations. ∗P < 0.05; #P < 0.05. n.s: not significantly different. 
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3.7 Effect of CPI-17 downregulation on endothelial permeabiity  
 
To analyze the role of CPI-17 in endothelial barrier function, the content of 
endogenous CPI-17 was reduced by gene silencing. Treatment of endothelial cells 
with CPI-17-specific siRNA caused a significant reduction in the amount of CPI-17 
protein compared to the control siRNA treatment (Fig. 3.11A). Albumin 
permeability of endothelial monolayers of CPI-17-depleted cells in absence and 
presence of thrombin was determined compared to cells treated with non-specific 
control siRNA. CPI-17 depletion did not affect basal permeability. However, in CPI-
17 depleted cells the maximum effect of thrombin on permeability after 10 minutes 
was reduced by 35% compared to the corresponding effect on endothelial cells 
treated with non-specific control siRNA (Fig. 3.11B). 
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Fig. 3.11   Effect of thrombin (Thr) on albumin permeability of endothelial 
monolayers treated with CPI-17 or control siRNA. (A) Representative western 
blots with an anti-CPI-17 antibody or an anti-vinculin antibody. (B) Effect of Thr 
(0.2 IU/ml) on albumin permeability. Data are means ± SD of 5 separate 
experiments with independent cell preparations. At time points between 6 and 30 
minutes, the albumin permeability in the presence of Thr in CPI-17 siRNA treated 
monolayers is significantly different from the control siRNA treated monolayers; 
∗P < 0.05. 
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4 Discussion  
 
4.1 Main Findings 
In the present study the molecular targets of the cAMP/PKA pathway 
controling the activation state of the endothelial contractile machinery, an 
important determinant of endothelial barrier function, were investigated. FSK, a 
direct activator of adenylyl cyclase, reduced basal permeability as well as 
antagonized thrombin-induced hyperpermeability. These effects on permeability 
were accompanied by related changes in MLC phosphorylation, the key regulator 
of the contractile machinery in endothelial cells. The effects of forskolin on both 
parameters were abolished by a specific inhibitor of PKA, PKI. PKI is a small (22 
amino acid) peptide, and  constitutes the inhibitory domain of PKI-protein (a 75 
amino acid small protein), isolated originally from rabbit muscle (Scott et al., 1985). 
It can specifically bind to the catalytic subunit of PKA (Walsh et al., 1971) and 
provides greater selectivity to PKA inhibition than the pharmacological agents. 
These data show that in the cell model used in this study, the effects of activation 
of adenylyl cyclase on endothelial barrier function and the contractile machinery 
are mediated by PKA.  
The present study focuses on the regulation of myosin light chain 
phosphatase. The major findings are (1) that activation of adenylyl cyclase by FSK 
reduces basal permeability and MLC phosphorylation. It also antagonizes the 
effect of thrombin on both parameters. (2) FSK induces the recruitment of the 
catalytic subunit PP1 and the myosin targeting subunit MYPT1 to myosin. This 
recruitment leads to an increase in phosphatase activity of the formed complex. (3) 
FSK reduces the inhibitory phosphorylation of MYPT1 at threonine 850 and also 
antagonizes the thrombin-induced phosphorylation at that site. (4) FSK reduces 
the interaction of PP1 with the endogenous inhibitor CPI-17. This reduction is 
accompanied by dephosphorylation of CPI-17 at its activation site threonine 38. 
FSK also antagonizes the thrombin effect on this endogenous inhibitor of PP1. 
The data of the present study shows that FSK can cause activation of the MLCP 
by two principal mechanisms: it induces the assembly of the MLCP holoenzyme 
complex and its recruitment to myosin, and activates the phosphatase by 
dephosphorylation and release of the regulatory inhibitor CPI-17. 
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It is well known that agents increasing intracellular levels of cAMP relax both 
endothelial and smooth muscle cells (Morel et al 1989; McDaniel et al., 1994; Stull 
et al., 1991). However, the target sites of cAMP/PKA on the contractile apparatus 
is still not clear. The phosphorylation level of MLC, the key regulator of contractile 
activity, is controlled by the balanced activities of at least two enzymes: the Ca2+-
calmodulin dependent myosin light chain kinase (MLCK) and myosin light chain 
phosphatase. Studies analyzing the mechanism of cAMP/PKA on MLCK inhibition 
have mainly focused on the Ca2+ lowering effect of cAMP in non-vascular smooth 
muscle cells. Recently Azam and co-workers (2007) have shown that cAMP 
relaxes vascular smooth muscle cells without affecting Ca2+ homeostasis. 
However, MLCK may also be modulated by direct PKA-dependent 
phosphorylation. In line with this concept, it has been reported that in smooth 
muscle cells PKA can phosphorylate MLCK (de Lanerolle et al., 1984). However, 
there is no report that this phosphorylation also affects the activity of MLCK.  
Studies investigating the effects of cAMP on endothelial permeability found no 
alterations on Ca2+ homeostais, suggesting that cAMP protects endothelial barrier 
in an Ca2+-independent manner (Carson et al., 1989). Garcia and co-workers 
(1997) reported that augmentation of cAMP levels increased phosphorylation and 
reduced the activity of MLCK endothelial cells. In contrast, Goeckeler and 
Wysolmerski (2005) have demonstrated that activation of cAMP/PKA pathway 
does not lead to phosphorylation of MLCK and does not affect the activity of 
MLCK. Previous data from our laboratory (Bindewald et al., 2004) has shown that 
maneuver increasing the cellular cAMP levels can lead to slight inhibition of MLCK 
activity in porcine aortic endothelial cells. However, this reduction in MLCK activity 
can not explain the increase in the velocity of MLC dephosphorylation in response 
to the elevation of cAMP level. Thus, inhibition of MLCK is of minor, if any, 
importance for the cAMP/PKA-induced inactivation the contractile machinery. 
 
4.2 MLCP holoenzyme complex formation and activation  
 
If the MLCK inhibition can be ruled out, activation of the MLCP is the most 
obvious target of the cAMP/PKA pathway to reduce the activation state of the 
contractile machinery. The activation of MLCP requires the assembly of the MLCP 
holoenzyme complex and its recruitment to phosphorylated MLC (Terrak et al., 
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2004). In the present study, major components of the holoenzyme complex, i.e. 
PP1 and MYPT1, were found to be associated with MLC already under the basal 
conditions in non-stimulated cells. This recruitment was demonstrated by co-
immunoprecipitation with specific antibodies, targeting both components of MLCP, 
MYPT1 and PP1. FSK increased the recruitment of PP1 to MYPT1. The binding of 
MLC to the MYPT1 containing complex was also increased. Western blot analysis 
showed a 4.5-fold increase in MLC/MYPT1 association as compared to a 2.5-fold 
increase in PP1/MYPT1 interaction. Irrespective of the possible differences in non-
linearities of co-immunoprecipitations for MLC and PP1, the increase in MLC 
association with the MLCP complex correlates with the dephosphorylation of MLC, 
suggesting an increase in affinity of MLCP holoenzyme for MLC. Measurement of 
phosphatase activity of the immunoprecipitated MLCP complexes showed that the 
PP1 activity is increased corresponding to its binding to MYPT1. This indicates 
that recruitment of PP1 to MYPT1 is of central importance for the activation of the 
MLCP complex by the cAMP/PKA pathway.  
The activity of the phosphatase in the immunoprecipitated complex was 
completely blocked by addition of recombinant inhibitor-2 (rec. I-2), which has 
been shown to specifically abrogate PP1 activity in phosphatase assays (Härtel et 
al., 2007). This supports the assumption that the increase in phosphatase activity 
is due to an increase in the MLCP specific phosphatase PP1, and excludes the 
recruitment of other phosphatases. 
As a specific substrate of MLCP, MLC co-immunoprecipitates with MYPT1 and 
PP1. However, in this study it remains unclear as to what extent this is due to a 
direct interaction of MYPT1 with MLC or with the catalytic subunit PP1. The co-
immunoprecipitation of MLC gives rise to the question whether the 
immunoprecipitates could contain even other phosphatases attached to the actin 
part of actomyosin. The close correspondence between the recruitment of PP1 
into the complex and the rec. I-2-sensitive inhibition of its activity, however, 
renders these possible contaminants of minor importance. 
 
4.3 Forskolin induced MLCP complex formation is independent of 
RhoA/Rock pathway 
Activation of the RhoA/Rock pathway is one of the most important regulatory 
steps in basal, and agonist-mediated inhibition of MLCP. RhoA, a member of the 
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Ras superfamily, has been implicated as the Ca2+-independent regulator of non-
muscle and smooth muscle cell contraction. RhoA cycles between its inactive 
(GDP-bound) and active (GTP-bound) form (Nobes and Hall, 1995). Activation of 
RhoA leads to its translocation to the cell membrane (Takaishi et al., 1996). The 
GTP-bound form of RhoA then interacts with the downstream effectors and 
transmits the signals. RhoA regulates cellular tension through its effector kinase, 
RhoA-dependent kinase (Rock). Active Rock catalyzes the phosphorylation of 
MYPT1 and is assumed to cause inactivation of MLCP. In smooth muscle cells it 
was also shown that Rock can directly phosphorylate the regulatory MLC (Somlyo 
and Somlyo 2003, Fukata et al 2001). Phosphorylation of either substrate results 
in a net increase in MLC phosphorylation, activation of the contractile machinery 
and contraction. 
It is well known that the phosphorylation state of MLC is regulated 
antagonistically by the cAMP/PKA and RhoA/Rock pathways (Essler et al., 2000). 
Activation of cAMP/PKA pathway leads to a decrease while activation of 
RhoA/Rock pathway leads to an increase in phosphorylation of MLC in smooth 
muscle cells as well as in endothelial cells. Studies both in vitro and in vivo 
(Ellerbroek et al., 2003; Lang et al., 1996; Essler et al., 2000) have shown that 
PKA can phosphorylate RhoA and this phosphorylation has been proposed as a 
molecular mechanism by which cAMP directly inactivates RhoA or indirectly RhoA 
effectors. In a recent study Goeckeler and Wysolmerski (2005) have shown that in 
endothelial cells cAMP/PKA activation led to RhoA phosphorylation accompanied 
by a reduction in its activity. Qiao et al., (2003) showed that cAMP inhibited 
thrombin-induced RhoA activation in microvascular endothelial cells. Consistent to 
these previous reports, in the present study it was confirmed that exposure of 
endothelial cells to FSK resulted in a 50% inhibition of RhoA translocation to the 
membrane under basal conditions. FSK completely blocked RhoA translocation to 
the membrane in thrombin stimulated cells. 
Therefore, in context of the study, the question was analyzed whether 
cAMP/PKA mediates its effect on MLCP complex formation via inhibition of the 
RhoA/Rock pathway and/or via other, yet unknown mechanisms. For that reason 
Rock was blocked by a specific pharmacological inhibitor Y27632 (Fu et al., 1998), 
and the effect of cAMP/PKA on MLC phosphorylation and assembly of the MLCP 
was determined. Inhibition of Rock alone led to a partial reduction of MLC 
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phosphorylation. Stimulation of cAMP/PKA pathway in Rock inhibited cells 
reduced MLC phosphorylation to almost zero. Immunoprecipitation experiments in 
the presence of Rock inhibitor showed that Rock inhibition does not lead to 
recruitment of PP1 to MYPT1. This  indicates that RhoA/Rock inhibition does not 
enhance MLCP complex formation and that cAMP/PKA-induced assembly of 
MLCP complex most probably is independent of Rock inhibition. Recently, we 
have shown that extracellular ATP can also induce MLCP holoenzyme complex 
formation in endothelial cells (Härtel et al., 2007). Interestingly, ATP does not 
inhibit RhoA activation in endothelial cells (Gündüz et al., 2003), indicating that 
induction of MLCP complex formation  by ATP is also independent of RhoA 
inhibition. In another study Ruegg et al., (1981) have shown that in smooth muscle 
cells, cAMP and cGMP can activate MLCP independent of RhoA/Rock inhibition. 
Similarly Surks and co-workers (1999 and 2003) demonstrated that PKG can 
directly interacts with MYPT1 and activates MLCP. This suggests that RhoA/Rock-
independent induction of MLCP complex formation by cAMP/PKA might involve a 
direct interaction of PKA with MLCP, however, there is no evidence for this 
interaction untill now and further studies are required to investigate this interaction. 
 
4.4 MYPT1 dephosphorylation 
 
A second level of regulation of MLCP activity is the phosphorylation state of 
MYPT1 at two threonine residues, T696 and T850. It is generally accepted that in 
smooth muscle cells the phosphorylation of these two sites is regulated mainly by 
Rock and to some extent by other kinases causing MLCP inactivation and/or 
dissociation of MLCP from myosin (Muranyi et al., 2002; Feng et al., 1999; 
McDonald et al., 2001; Velasco et al 2002). It has been shown recently, that 
stimulation of endothelial cells with thrombin induces a Rock-mediated increase in 
phosphorylation of MYPT1 at T850 and T696 (Birukova et al., 2004, Härtel et al., 
2007). The results of the present study demonstrate that activation of the 
cAMP/PKA pathway antagonizes the effect of thrombin at these strategic sites of 
MYPT1, since FSK could completely abolish the effect of thrombin on T696 and 
T850 phosphorylation. Furthermore RhoA translocation studies and pulldown 
assays show that FSK effectively blocks RhoA translocation and activation under 
basal conditions as well as thrombin induced RhoA translocation and activation. 
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This indicates that cAMP/PKA induced MYPT1 dephosphorylation involves 
inhibition of RhoA/Rock pathway. 
 
4.5 cAMP/PKA signaling inactivates CPI-17 
 
Data from smooth muscle cells shows that in addition to MYPT 
phosphorylation, the activity of the MLCP complex can be controlled by variety of 
other mechanisms. Today several small molecular weight endogenous inhibitory 
proteins are known to regulate MLCP activity by direct interaction with PP1 
catalytic subunit. One of the most prominent and specific endogenous inhibitor of 
PP1 is a small protein CPI-17 (Eto et al., 1995), which initially was assumed to be 
expressed only in smooth muscle cells. However, a recent report by Kolosova and 
co-workers (2004) shows the expression of CPI-17 also in endothelial cells. CPI-
17 can inhibit MLCP holoenzyme complex as well as PP1 catalytic subunit (Eto et 
al., 1995; 1999). Most of our understanding about CPI-17-induced inhibition of 
MLCP and PP1 are from studies in smooth muscle cells. It has been proposed that 
inflammatory mediators (e.g. histamine and thrombin)-induced phosphorylation of 
CPI-17 at threonine 38 (T38) potentiates its MLCP/PP1-inhibitory activity both in 
smooth muscle cells and endothelial cells (Kitazawa et al., 2000; Kolosova et al., 
2004) but precise mechanism is still unknown. Structure activity study (Ohki et al., 
2001) shows that phosphorylation of CPI-17 at T38 leads to conformational 
changes which may expose an inhibitory motif to the PP1 catalytic subunit. 
Accumulating evidence shows that cAMP and cGMP exert stimulating effects on 
MLCP by acting on more than a single target (Somlyo and Somlyo, 2003). In the 
present study, it was analyzed whether cAMP/PKA signaling mechanism can exert 
its effect on MLCP via direct influence on the PP1 catalytic subunit were 
examined. Co-immunoprecipitation experiments show for the first time the 
existence of CPI-17/PP1 complexes in endothelial cells. Activation of cAMP/PKA 
pathway reduced the interaction of CPI-17 with PP1 and led to dissociation of the 
CPI-17/PP1 complex, with a corresponding increase in PP1 activity. Stimulation of 
endothelial cells with thrombin induced CPI-17/PP1 complex formation and a 
corresponding decrease in PP1 activity. This complex formation and MLCP 
inactivation was effectively blocked by FSK. 
Phosphorylation of CPI-17 has been reported to induce its inhibitory activity 
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towards PP1 (Kitazawa et al., 2000). In vitro studies indicate that CPI-17 can be 
phosphorylated at T38 and hence be activated by multiple kinases including PKC 
(Eto et al., 1995) and Rho kinase (Koyama et al., 2000). In intact endothelial and 
non-endothelial cells, only PKC and Rock have been reported to phosphorylate 
CPI-17 (Kolosova et al., 2004; Pang et al., 2005; Sakai et al., 2006). In the present 
study it was shown by western blot analysis that FSK reduces basal CPI-17 
phosphorylation by 50%. This dephosphorylation corresponds with a decrease in 
CPI-17/PP1 complex to the same extent and a 60% increase in PP1 activity. 
Contrariwise, thrombin induced a 50% increase in CPI-17 phosphorylation 
corresponding to 1.6-fold increase in CPI-17/PP1 complex formation and a 40% 
reduction in phosphatase activity.  
To this point, the results left the question open whether the effect of the 
cAMP/PKA pathway on CPI-17 phosphorylation is due to an interference with the 
RhoA/Rock pathway or not. This question also can be addressed for the “basal” 
conditions of this study, since these imply also a basal activity of the latter pathway 
as indicated by some membrane binding of RhoA and the ability of the Rho-kinase 
inhibitor Y27632 to lower MYPT1 phosphorylation under basal conditions. To 
answer this question, the effect of Rho kinase inhibitor Y27632 was studied on 
CPI-17 phosphorylation. At maximal effective concentrations, Y27632 induced 
dephosphorylation of CPI-17 to 60% of the basal level. Copresence of Y27632 and 
FSK lead to nearly complete CPI-17 dephosphorylation. This indicates the 
existence of at least two mechanisms regulating the phosphorylation state of CPI-
17. One is Rock-dependent and the other is -independent.   
A recent study in smooth muscle cells has shown that activation of integrin 
linked kinase (ILK) via PI3K pathway can cause phosphorylation of CPI-17 in a 
Rock independent manner (Huang et al., 2006). Furthermore Stevens et al., 
(2004) have shown in human platelets that thrombin induced activation of ILK in a 
PI3K dependent manner.  However, there is no study showing that cAMP/PKA 
inhibits ILK.  
Taken together, this study indicates that in endothelial cells cAMP/PKA 
pathway can activate myosin phosphatase by at least two mechanisms: inhibition 
of Rock-dependent phosphorylation of MYPT1, CPI-17 phosphorylation and as 
shown here for the first time, by inhibition of CPI-17 interaction with PP1.  
 
  
57
 
4.6 CPI-17 as mediator of thrombin induced barrier failure 
Finally, experiments using siRNA directed against CPI-17, illustrated a 
functional role of CPI-17 and PP1 activation in thrombin induced barrier failure. 
Specific siRNA down-regulated CPI-17 protein by approximately 70%. This down-
regulation attenuated the thrombin effect on endothelial barrier function by 35%. 
This is in accordance with a 50% increase in CPI-17 phosphorylation, a 1.5-fold 
increase in CPI-17/PP1 complex formation and a 40% decrease in PP1 activity.  
Changes in macromolecular permeability result from complex changes in the 
contractile activation and cell-cell and cell matrix adhesion. The fact that  
downregulation of an endogenous inhibitor of the catalytic subunit of the MLCP 
complex, as only one element in complex mechanism can lead to a one-third-
reduction of the effect, demonstrates the relative importance of this regulatory 
protein. In a previous report Kolosova and colleagues (2004) showed that in 
endothelial cells the effect of thrombin had no profound effect on CPI-17 
phosphorylation and depletion of CPI-17 in these cells could not attenuate the 
thromin effect significantly. This might have been due to the use of higher passage 
endothelial cells in the study. In this study either primary endothelial cells or cells 
of passage one were used. 
In summary, activation of the cAMP/PKA pathway protects the endothelial 
barrier function mainly via activation of MLCP. The novel findings are that 
cAMP/PKA pathway targets the MLCP complex at multiple sites. These include: (i) 
inhibition of upstream inactivating pathway e.g. Rho/Rock, thus shielding from 
inactivation (ii) induction of MLCP holoenzyme complex formation, thus providing 
quantitively increased levels of active MLCP to the contractile machinery, and (ii) 
activation of the catalytic subunit PP1 mainly by inactivating the inhibitory CPI-17. 
This activation of MLCP overrides the inhibitory pathways induced by inflammatory 
mediators.  
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Fig. 4.1 Schematic presentation of inactivation of contractile machinery via 
activation of myosin light chain phosphatase (MLCP) by cAMP/PKA pathway. 
Activation RhoA/Rock pathway by thrombin leads to phosphorylation of myosin 
phosphatase targeting subunit (MYPT1) at threonine 850(T850). It also leads to 
phosphorylation of CPI-17 and its increased interaction with PP1 catalytic subunit. 
This causes the inactivation of MLCP, an increas in phosphorylation of myosin 
light chain (MLC), actin myosin interaction and contraction. Activation of 
cAMP/PKA pathway leads to dephosphorylation of MYPT1 and an increase in 
recruitment of PP1 catalytic subunit and MYPT1 to myosin. Dephosphorylation of 
CPI-17 facilitates its dissociation from PP1 catalytic subunit. All these events 
cause activation of MLCP, dephosphorylation of MLC and endothelial cell 
relaxation. 
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4.7  Future perspective 
 
Endothelial barrier dysfunction is a frequent cause of vascular leakage during 
inflammation. Elevation of cAMP can effectively block this leakage and is already 
being used in clinical situations with some limitations. β-adrenergic agonists in 
combination with phosphodiesterase inhibitors are applied to increase the cellular 
contents of cAMP. However, therapeutic use of β-adrenergic agonists and 
phosphodiesterase inhibitors leads to rapid desensitization of endothelial cells to 
these agents i.e. tachyphylaxis or tolerance, that leads to shortening the time of 
their effective application to reduce vascular leakage (Doorenbos et al., 1989; 
Droder et al., 1992). Secondly, endothelial cells from different vascular 
provenience do not respond similarly to cAMP elevating agents agents. 
Endothelial cells from microvasculature of the coronary and brain circulation do not 
respond with a reduction in permeability, but rather with an increase (Hempel et 
al., 1996; Palmer et al., 1986). Similarly, cAMP increasing agents have different 
effects on different cell types. It has been shown that in endothelial cells, β-
adrenergic agonists lead to protetection against barrier failure, however, in the 
same animal increased cAMP levels only in smooth muscle cells leads to 
increased vascular leakage (Warren et al., 1993). These unwanted side effects of 
cAMP elevating agents limit their use in clinical conditions. The knowledge of the 
targets of cAMP/PKA pathway can harnessed for the development of more 
specific therapeutic strategies targeting endothelial cells. One such target could be 
CPI-17. Knockdown of this protein leads to a 1/3 reduction in the effect of 
thrombin. Development of specific pharmacological inhibitors against CPI-17 might 
be an important innovation to block vascular leakage during pathophysiological 
conditions. 
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6 Summary 
 
Endothelial barrier dysfunction is often the underlying cause of capillary 
leakage during pathophysiological conditions like inflammation and ischemia 
reperfusion. Maneuvers increasing intracellular levels of cAMP protect against 
imminent failure of endothelial barrier function induced by inflammatory mediators 
or ischemia-reperfusion. This protective effect is mainly due to an inactivation of 
the contractile machinery, a primary determinant of endothelial barrier function. 
The activation of the contractile machinery is regulated by the phosphorylation 
state of the regulatory myosin light chains (MLC), which is controlled by balanced 
but antagonistic activities of myosin light chain phosphatase (MLCP) and myosin 
light chain kinase (MLCK). Here the molecular mechanisms by which cAMP/PKA 
induced the activation of the MLCP leading to inactivation of the contractile 
machinery were analyzed. In cultured human umbilical vein endothelial cells  
activation of adenylyl cyclase by forskolin (FSK) reduced basal macromolecule 
permeability and caused dephosphorylation of MLC. It also antagonized thrombin-
induced increase of both parameters. FSK stimulated the formation of MLCP 
holoenzyme complex, i.e. it induced the recruitment of the protein phosphatase 1 
(PP1) catalytic subunit and myosin phosphatase targeting subunit (MYPT1) to 
myosin, and activation of the PP1 catalytic subunit. FSK inhibited the RhoA/Rock 
pathway leading to dephosphorylation of MYPT1. It caused dephosphorylation of 
the PP1 inhibitory protein CPI-17 at threonine 38 and its detachment from the PP1 
catalytic subunit. FSK also blunted the thrombin-induced effect on MYPT1 and 
CPI-17 phosphorylation. Down regulation of CPI-17 by siRNA attenuated the 
thrombin effect on endothelial permeability by 35 %. The data of the present study 
show that stimulation of adenylyl cyclase causes assembly and activation of the 
MLCP holoenzyme complex and thereby stabilizes endothelial barrier function. 
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7 Zusammenfassung 
 
Das Versagen der endothelialen Schrankenfunktion ist eine häufige 
Ursache für die Entstehung eines „Capillary leakage“ im Rahmen einer 
Entzündung oder Ischämie/Reperfusion. Manöver, die die intrazelluläre cAMP-
Konzentration steigern, schützen vor einem drohenden Verlust der 
Schrankenfunktion.  Dieser Schutzeffekt beruht hauptsächlich auf einer 
Inaktivierung des kontraktilen Apparates, der ein wesentlicher Faktor der 
endothelialen Schrankfunktion ist. Der Aktivierungszustand des kontraktilen 
Apparates wird durch den Phosphorylierungsgrad der regulatorischen leichten 
Kette des Myosins (MLK) geregelt, welche durch die antagonistische Wirkung der 
MLK-Phosphatase (MLKP) und MLK-Kinase (MLKK) kontrolliert wird. 
In kultivierten humanen Endothelzellen der Nabelschnurvene reduziert die 
Aktivierung der Adenylylzyklase durch Forskolin (FSK) die basale 
Makromolekülpermeabilität und löst eine Dephosphorylierung der MLK aus. FSK 
antagonisiert auch die Thrombin-induzierte Steigerung beider Parameter. FSK 
stimuliert die Bildung des MLCP Holoenzymkomplexes, d.h. es induziert die 
Rekrutierung der Proteinphosphatase (PP1)-Untereinheit und der Myosin-
Phosphatase-bindenden Untereinheit (MYPT1) an Myosin und aktiviert die PP1-
Untereinheit. FSK hemmt den RhoA/Rock weg, was zu einer Dephosphorylierung 
von MYPT1 führt. Es induziert die Dephosphorylierung des PP1-inhibitorischen 
Proteins CPI-17 an Threonin 38 und seine Lösung von der PP1-Untereinheit. FSK 
vermindert auch die Thrombinwirkung auf die MYPT1 und CPI-17-
Phosphorylierung. Die Herunterregulation von CPI-17 durch siRNA verminderte 
die Thrombin-induzierte Zunahme der endothelialen Permeabilität. 
Die Daten der vorliegenden Untersuchung zeigen, dass die Stimulation der 
Adenylylzyklase die Assemblierung und Aktivierung des MLKP-Komplexes auslöst 
und dadurch die endotheliale Schranke stabilisiert und vor einem drohenden 
Versagen schützt.  
 
  
78
 
8 Erklärung 
 
„Ich erkläre: Ich habe die vorgelegte Dissertation selbständig und ohne unerlaubte 
fremde Hilfe und nur mit den Hilfen angefertigt, die ich in der Dissertation 
angegeben habe. Alle Textstellen, die wörtlich oder sinngemäß aus 
veröffentlichten Schriften entnommen sind, und alle Angaben, die auf mündlichen 
Auskünften beruhen, sind als solche kenntlich gemacht. Bei den von mir 
durchgeführten und in der Dissertation erwähnten Untersuchungen habe ich die 
Grundsätze guter wissenschaftlicher Praxis, wie sie in der „Satzung der Justus-
Liebig-Universität Gießen zur Sicherung guter wissenschaftlicher Praxis“ 
niedergelegt sind, eingehalten.“ 
 
 
 
 
 
 
 
 
Gießen, den.....................      .............................. 
         Muhammad Aslam 
 
  
79
 
9  Appendix 
 
9.1  Chemicals and consumables 
6-amino hexanoic acid   Merck, Darmstadt, Germany 
Acrylamide solution (40%; wt/vol)  Amersham Pharmacia, UK 
Acrylamide     Carl Roth, Karlsruhe, Germany 
Ammonium persulfate SERVA, Heidelberg, Germany 
Ammonium sulfate Merck, Darmstadt, Germany 
ATP      Roche, Mannheim, Germany 
Benzonase®     Merck, Darmstadt, Germany 
bFGF      PromoCell, Heidelberg, Germany 
Bisacrylamide solution (2%; wt/vol) Amersham Pharmacia, UK 
Bisacrylamide    Carl Roth, Karlsruhe, Germany 
Bovine serum albumin   Sigma-Aldrich, Steinheim, Germany 
Bromophenol blue    Sigma-Aldrich, Steinheim, Germany 
Caffein     Sigma-Aldrich, Steinheim, Germany 
Calcium chloride    Merck, Darmstadt, Germany 
Calyculin A     Calbiochem, Bad Soden, Germany 
Cantharidin     Calbiochem, Bad Soden, Germany 
Collagenase II    PAA Labs., Pasching, Austria 
Complete® inhibitor cocktail  Roche, Mannheim, Germany 
Culture dishes    BD, Heidelberg, Germany 
Diethyl ether     Merck, Darmstadt, Germany 
Dimethyl sulfoxide    Sigma-Aldrich, Steinheim, Germany 
Di-sodium hydrogen phosphate  Carl Roth, Karlsruhe, Germany 
Dithiothreitol Amersham Pharmacia, UK 
EDTA      Carl Roth Karlsruhe, Germany 
EGTA      Boehringer, Mannheim 
Endothelial cell basal medium® kit PromoCell, Heidelberg, Germany 
Endothelial cell growth supplement PromoCell, Heidelberg, Germany 
Eppendorf tubes (0.5, 1.5, 2 ml)  Eppendorf, Hamburg, Germany  
Falcon tubes (50 ml, 12 ml)  BD, Heidelberg, Germany 
FCS      PAA, Pasching, Austria  
Filter papers     Biotech-Fischer, Reiskirchen, Germany 
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Forskolin     Calbiochem, Bad Soden, Germany 
FuGENE® 6     Roche, Mannheim, Germany 
Gentamycin     Gibco BRL, Eggenstein, Germany 
Glass cover slips    Menzel, Braunschweig, Germany 
Glycerol (100%)    Sigma-Aldrich, Steinheim, Germany 
Glycerol (87%) Amersham Pharmacia, UK 
Glycine     Carl Roth, Karlsruhe, Germany 
HBSS      PAA, Pasching, Austria 
hEGF      PromoCell, Heidelberg, Germany 
HEPES     Sigma-Aldrich, Steinheim, Germany 
Human recombinant inhibitor 2  New England Biolabs, Frankfurt, Germany 
Hydrocortisone    PromoCell, Heidelberg, Germany 
Imidazole     Merck, Darmstadt, Germany 
Magnesium chloride   Fluka, Switzerland 
Magnesium sulfate    Merck, Darmstadt, Germany 
Manganese chloride    Merck, Darmstadt, Germany 
β-mercaptoethanol    Merck, Darmstadt, Germany 
Methanol     Merck, Darmstadt, Germany 
Millipore water    Millipore, Eschborn, Germany 
Molecular weight marker   Sigma-Aldrich, Steinheim, Germany 
Nitrocellulose membrane   Schleicher und Schuell, Dassel, Germany 
Non-fat milk powder   Applichem, Darmstadt, Germany, 
Nonidet P-40    Sigma-Aldrich, Steinheim, Germany 
Okadaic acid     Calbiochem, Bad Soden, Germany 
γ-[32P]-ATP     Amersham Pharmacia, UK 
Penicillin/streptomycin   Gibco BRL, Eggenstein, Germany 
Phosphorylase-b    Sigma-Aldrich, Steinheim, Germany 
Phosphorylase-kinase   Sigma-Aldrich, Steinheim, Germany 
Pipette tips     Eppendorf, Hamburg, Germany 
Pipettes     Eppendorf, Hamburg, Germany 
PKI      Calbiochem, Bad Soden, Germany 
PMSF      Sigma-Aldrich, Steinheim, Germany 
Ponceau S solution SERVA, Heidelberg, Germany 
Potassium chloride    Merck, Darmstadt, Germany 
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Potassium dihydrogen phosphate  Merck, Darmstadt, Germany 
Protein G-coated magnetic beads Dynal, ASA, Oslo, Norway 
Recombinant PP1    New England Biolabs, Frankfurt, Germany 
Rhotekin-RBD    Upstate, USA  
Rubber policeman    BD, Heidelberg, Germany 
Scalpal (disposble)    Feather, Japan 
See Blue® (pre-stained marker)  Invitrogen GmbH, Karlsruhe, germany 
siRNA      Qiagen, Hilden, Germany 
Sodium azide    Merck, Darmstadt, Germany 
Sodium bicarbonate   Carl Roth, Karlsruhe, Germany 
Sodium chloride    Carl Roth, Karlsruhe, Germany 
Sodium di-hydrogen phosphate  Carl Roth, Karlsruhe, Germany 
Sodium dodecyl sulfate   SERVA, Heidelberg, Germany 
Sodium fluoride    Sigma-Aldrich, Steinheim, Germany 
Sodium hydroxide    Carl Roth, Karlsruhe, Germany 
Sodium orthovanadate   Sigma-Aldrich, Steinheim, Germany 
Sodium thioglycolate   Sigma-Aldrich, Steinheim, Germany 
Sterile filters (0.22 µm)   Sartorius, Goettingen, Germany 
Sterile pipettes    BD, Heidelberg, Germany 
Sucrose     Sigma-Aldrich, Steinheim, Germany 
Super signal-west® (ECL solution) Pierce biotech, Bonn, Germany 
Syringes (20 ml, 2 ml)   BD, Heidelberg, Germany 
TEMED     Sigma-Aldrich, Steinheim, Germany 
Thrombin     Behring, Marburg, Germany 
Transwell® membrane filters   Corning, NY, USA 
Tricholoroacetic acid   Merck, Darmstadt, Germany 
Tris base     Carl Roth, Karlsruhe, Germany 
Tritone X-100 SERVA, Heidelberg, Germany 
Trypsin-EDTA    Gibco-BRL, Eggenstein, Germany 
Tween 20 Amersham Pharmacia, UK 
Urea  Amersham Pharmacia, UK 
Whatman® 3 MM filter paper  Millipore, Eschborn, Germany 
Y27632     Calbiochem, Bad Soden, Germany 
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9.2  Antibodies 
 
Primary antibodies 
Antibodies     Source 
CPI-17 (Rabbit IgG polyclonal)  Upstate, Charlottesville, VA, USA 
Phospho CPI-17  
(Rabbit IgG polyclonal)   Upstate, Charlottesville, VA, USA 
MLC (Mouse IgM monoclonal)  Sigma, Steinheim, Germany 
MYPT1 (Sheep IgG polyclonal)  Upstate, Charlottesville, VA, USA 
Phospho MYPT696  
(Rabbit IgG polyclonal)   Upstate, Charlottesville, VA, USA 
Phospho MYPT850  
(Rabbit IgG polyclonal)   Upstate, Charlottesville, VA, USA 
PP1δ (Rabbit IgG polyclonal)  Upstate, Charlottesville, VA, USA 
RhoA (Mouse IgG monoclonal)  Santa Cruz Biotechnology, Heidelberg,  
      Germany 
Vinculin (Clone hVIN-1) 
(Mouse IgG monoclonal)   Sigma, Steinheim, Germany 
 
Secondary antibodies (HRP-labeled) 
Antibody     Source 
Anti Mouse IgG    BD Bioscience, Heidelberg, Germany 
Anti Mouse IgM    Sigma, Steinheim, Germany 
Anti Rabbit IgG    Upstate, Charlottesville, VA, USA 
Anti Sheep IgG    Santa Cruz Biotechnology, Heidelberg,  
      Germany 
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9.3  Laboratory instruments 
 
Beckman Allegra 64R centrifuge  Beckman Coulter, USA 
Beckman TL 100 ultracentrifuge  Beckman Coulter, USA 
Blotting chambers    Biotech-Fischer, Reiskirchen, Germany 
Electrophoresis apparatus   Biometra, Goettingen, Germany 
Gel documentation system  Quantity One series, Bio-Rad, Munich,  
Germany 
Glass ware     Schott, Mainz, Germany 
Hamilton syringe    Hamilton, Bonaduz, Switzerland 
Incubators     Heraeus, Hanau, Germany 
Laminar flow hood    Heraeus, Hanau, Germany 
Tri-Carb 1600 TR liquid scintillation  
counter     Packard Instrument Company, CT, USA 
Magnet stirrer    Jahnke und Kunkel, Staufen, Germany 
Magnetic rack    DYNAL, Oslo, Norway 
Neubauer chamber    Superior, Marienfeld, germany 
Phase contrast microscope  Olympus, Japan 
pH-Meter     WTW-Weinheim, Germany 
Photometer     Carl Zeiss, Jena, Germany 
Power supply    Biometra, Goettingen, Germany 
Rocker     Biometra, Goettingen, Germany 
Table top (centrifuge)   Eppendorf, Hamburg, Germany 
Vortexer     Heidolph, Kelheim, Germany 
Water bath     Julabo, Seelbach, Germany 
Water demineralisation unit  Millipore, Eschborn, germany 
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9.4  Solutions 
 
2x-SDS sample buffer 
Tris.HCl   250 mM 
Glycerol   20 % 
SDS    4 % (wt/vol) 
DTT    1 mM (wt/vol) 
β-mercaptoethanol  5 % (vol/vol) 
Cantharidin   10 µM 
Bromophenol Blue  0.001 % (wt/vol) 
 
10x TBS 
Tris/HCl   100 mM 
NaCl    1.6 M 
pH 7.4 
 
TBS Tween (TBST) 
1x TBS   1000 ml 
Tween 20   1 ml (0.1%, vol/vol) 
 
10X PBS  
Na2HPO4    0.1 M  
KH2PO4   17 mM  
NaCl    1.37 M 
KCl    27 mM 
 
0.1M Sodium Phosphate buffer (pH 7.4) 
 
Soln. A (0.2 M sodium dihydrogen phosphate) 
Dissolve 15.6 g sodium dihydrogen phosphate (dihydrate) in 500 mL dH20 
Soln. B (0.2 M di sodium hydrogen phosphate) 
Dissolve 17.8 g disodium hydrogen phosphate (dihydrate) in 500 mL dH20 
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Mix 57 ml of soln. A, 243 ml of soln. B with 600 ml of water. The pH would itself be 
adjusted to 7.4 
 
Urea-glycerol gel buffer    
Tris     240 mM   
Glycine    276 mM   
pH to 8.8 – 8.9 
 
Urea-glycerol gel lysis buffer (10 ml) 
Urea      554 mg (8.8 M) 
Urea-gel buffer   975 µl  
0.5 M DTT    225 µl (10 mM) 
1 M Sodium thioglycolate  56.2 µl (5 mM) 
100 mM Cantharidin  11.24 µl (10 µM) 
6 M Imidazole (pH 8.8)  112.4 µl (60 mM) 
Millipore water (qs)   10 ml 
Bromophenol blue    0.001% (wt/vol) 
 
Lysis buffer (Immunoprecipitation) 
Tris/HCl pH 7.4)    50 mM 
NaCl     150 mM  
Triton X-100    1 % 
Nonidet P - 40   0.5 % 
EDTA     1 mM 
EGTA     1 mM 
NaF     20 mM 
Na-orthovanadate   1.5 mM 
DTT     10 mM 
PMSF     0.5 mM 
Complete® protease inhibitor cocktail    
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RhoA pulldown assay 
Lysis buffer 
HEPES    25mM 
NaCl     150 mM 
MgCl2     5 mM 
EDTA     1 mM 
NaF     10 mM 
Na-orthovanadate   2 mM 
DTT     5 mM 
Tritone-X100    0.5% 
Glycerol    2 % 
PMSF     0.5 mM 
Complete® protease inhibitor cocktail   
 
Wash buffer 
Tris/HCl (pH 7.4)   25mM 
Triton X-100    1% 
NaCl     150 mM 
MgCl2     10 mm 
PMSF     0.5 mM 
Complete® protease inhibitor cocktail  
 
Lysis buffer (Membrane fractionation) 
Tris/HCl (pH 7.4)   5 mM  
Sucrose    250 mM 
EDTA     5 mM 
MgCl2     1 mM 
NaCl     5 mM 
DTT     10 mM   
PMSF     0.5 mM   
Complete® protease inhibitor cocktail   
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